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Summary 
Prostate cancer frequently metastasizes to the bone and becomes incurable. Recent 
studies have suggested that prostate cancer stem cells (CSCs) play key roles in the 
initiation, progression and treatment failure of the disease and therefore represent an 
ideal therapeutic target. Prostate CSCs share many similarities with normal stem 
cells, including dependency on a stem cell niche. Prostate CSCs that disseminate into 
the bone marrow are believed to manipulate the hematopoietic stem cell (HSC) niche 
to initially maintain a quiescent state before producing a new niche to support the 
development of bone metastasis. Therefore, a better understanding of the bone 
marrow stem cell niche and its role in supporting bone metastasis may aid the 
development of effective treatments.  
 
The main aim of my project was to investigate the role of osteoblasts and adipocytes, 
two major cellular components of the bone marrow, in the formation of a CSC-
specific niche during the development of prostate tumor bone metastasis. 
Specifically, I have studied the role of angiopoietin-1, a well-studied osteoblast-
secreted paracrine factor, in regulating the quiescence of prostate CSCs. cDNA 
microarray and real-time PCR (RT-PCR) analysis were used to elucidate the 
downstream mechanisms underlying the actions of Ang-1 in prostate CSCs. I have 
subsequently confirmed my findings by demonstrating that Ang-1 receptor (Tie-2) 
promotes prostate tumor bone metastasis in vivo.  
 
In the second part of my project, I  studied whether prostate CSCs manipulate 
adipocytes within the bone marrow to promote the formation of a CSC-specific 
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niche. I first established a novel 3D spheroid co-culture model to study the 
interactions between adipocytes and prostate CSCs. Using this model, I have tested 
the effects of adipocytes on CSC self-renewal and identified the key paracrine factors 
that mediate the crosstalk between these two cell types.  
 
The successful completion of this study has lead to the identification of a number of 
potential prognostic and therapeutic targets against prostate tumor bone metastasis. 
Further translation of my work may therefore help in improving the treatment 
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Chapter 1: Introduction 
1.1 Introductory Statement 
Prostate cancer is one of the most common solid tumors in men and is the second 
leading cause of morbidity and mortality in men worldwide [1]. When the tumor is 
localized, the disease is curable by prostatectomy. However, patients with advanced 
prostate cancer are normally treated with androgen ablation therapy. The therapy is 
effective initially as prostate cancer cells require androgen to grow and survive; 
however, the cancer cells eventually become androgen independent and develop 
metastatic, castration-resistant tumors [2]. At this stage, chemotherapy and 
radiotherapy exhibit only small benefits. As a result, advanced prostate cancer 
remains an incurable disease by current treatment strategies [3, 4].  
 
Most primary tumor cells enter the circulation and seed at secondary tissues during 
the formation of metastasis. In the secondary site, the primary tumor cells have to 
adapt to a new microenvironment, which normally lack nutrients and oxygen, before 
they can redevelop as macro metastases [5]. Bone is the most common site of cancer 
metastasis, especially in breast and prostate cancer. Ample evidence supports the 
idea that tumor metastasis originates from a rare subpopulation of cancer cells known 
as cancer stem cells (CSCs) [6]. CSCs are similar to normal stem cells, in that they 
can undergo an unlimited self-renewal [7, 8] and differentiate into heterogeneous 
lineages of cells [9]. Furthermore, the unique plasticity of CSCs also allows them to 
undergo a phenotypic switch known as epithelial to mesenchymal transition (EMT) 
which is believed to be the key event during cancer metastasis. EMT is a process in 
which epithelial cells with regular cell-cell junctions and adhesions convert into 
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motile and invasive cells with mesenchymal phenotypes [10]. Recent studies have 
reported a close relationship between CSCs and EMT [11]. More importantly, 
substantial analysis of tumor cells that disseminate into bone marrow has confirmed 
that most of these cells possess a CSC phenotype. What is not yet clear is why CSCs 
preferentially disseminate into the bone marrow.  
 
One possible reason is the presence of a stem cell niche in the bone marrow, which, 
under normal circumstances, helps to maintain the stemness of hematopoietic stem 
cells (HSCs). As demonstrated in previous studies, mesenchymal stem cells (MSCs) 
that reside in the bone cavity are responsible for differentiating into different types of 
marrow stromal cell lineages, including obsteoblasts, adipocytes, fibroblasts, 
chondrocytes, myocytes and endothelial cells [12]. Osteoblasts, in particular, are 
responsible for the formation of the osteoblastic niche that regulates the homing and 
self-renewal of HSCs [13]. This has been supported by in vivo studies which showed 
that HSC and progenitor cells mobilized to the periphery when there is a depletion of 
osteoblasts [14, 15]. Like HSCs, the stemness of CSCs is highly dependent on the 
presence of a stem cell niche. Interestingly, according to previous studies, CSCs are 
capable of creating their own CSC niche by recruiting MSCs derived from bone 
marrow, resulting in expansion of the CSC population within the primary tumor [16].  
On the other hand, CSCs can also ‘hijack’ the already established normal stem cell 
niches [5]. This has been demonstrated recently in a mouse model, where cancer 
cells have been shown to form micrometastases within the HSC niches by competing 
with the HSCs [17]. Therefore, a better understanding on the role of the bone marrow 
stem cell niche during development of prostate cancer metastasis may offer 
opportunities for new treatment strategies.  
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Adipocytes represent another major component within bone marrow, which 
contributes to more than half of the bone marrow. Although the role of adipocytes in 
prostate tumor bone metastasis is largely unclear, obesity, a condition associated with 
abnormal bone marrow adiposity, has been shown to correlate with prostate cancer 
development [18-20] and disease progression [21]. In a number of large cohorts, a 
higher body mass index was consistently found to increase the risk of prostate 
cancer. Obesity has also been found to correlate with prostate cancer relapse after 
prostatectomy [22] or radiation therapy [23]. 
 
Evidence from previous studies has demonstrated that prostate cancer cells are 
attracted to an adipocyte-rich metabolically active red bone marrow [24, 25]. 
Recently, bone marrow adipocytes have also been reported to stimulate prostate 
tumour growth in bone via an FABP4-dependent (Fatty acid binding protein 4) 
mechanism [26].  In addition,  prostate tumor cells are able to infiltrate into the 
periprostatic adipose tissues, which influences the phenotypic behaviour of 
malignant cells through modulation of adipokine secretion (adipokines are factors 
secreted by adipose tissues), extracellular matrix components and also via direct cell-
cell contact [27]. Adipocytes isolated from periprostatic adipose tissues were also 
found to induce invasiveness of prostate cancer cells [28]. Therefore, these findings 
support the idea that abnormal adipocyte function, possibly due to adjacent cancer 
cells or as a result of obesity, may contribute to a CSC niche that favours prostate 
tumor metastasis. In summary, understanding the role of osteoblasts and adipocytes 
in the formation of a CSC-specific niche may help in the development of new and 
effective treatments against metastatic prostate cancer, and as a result decrease the 
mortality and morbidity associated with these patients.  
 20 Dissecting the prostate cancer  stem cell niche inside the bone marrow. 
1.2 Hypothesis and Aims 
Research questions 1: Does the osteoblast-secreted paracrine Ang-1 promote 
prostate tumor bone metastasis by supporting the homing and colonization of 
prostate CSCs into the bone marrow? 
Osteoblasts within the bone marrow actively secret Ang-1 to maintain the quiescence 
and stemness of HSCs. Here, I hypothesize that Ang-1 also functions as a key stem 
cell factor which maintains the quiescence state of prostate CSCs during prostate 
tumor metastasis and enrichment of Ang-1 receptor, Tie-2 in prostate cancer cell 
population supports the homing and colonization of prostate CSCs into the bone 
marrow. These hypotheses will be tested by the following aims: 
 
 Determine the role of Ang-1/Tie-2 in the maintenance of prostate CSCs.  
 Determine the role of Ang-1/Tie-2 in the regulation of prostate CSCs 
quiescence.  
 Determine the role of Ang-1/Tie-2 in prostate tumor bone metastasis. 
 
Research Question 2: Do adipocytes contribute to the formation of a prostate 
CSC niche during the development of prostate tumor bone metastasis. 
Prostate tumor frequently metastasizes to the bone marrow, where half of the 
microenvironment is composed of adipocytes. However, it is not clear whether these 
fat storing cells play any roles in bone metastasis. Here, I hypothesize that during 
prostate tumor metastasis, prostate CSCs are the architects of their own stem cell 
niches through manipulation of adipocytes within the bone marrow. I will test this 
hypothesis by carrying out the following aims:  
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 Determine the role of adipocytes in the maintenance of prostate CSCs. 
 Determine the underlying mechanism that drives the active self-renewal of 
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1.3 Overview of research contributing to publication output 
In this PhD project, I have focused on studying the role of the two major components 
with in the bone marrow (i.e. osteoblasts and adipocytes) in prostate CSC self-
renewal and prostate tumor metastasis. As will be discussed in Chapter 2, prostate 
CSCs have been suggested to play an important role in the development, progression 
and treatment failure of prostate cancer. Meanwhile, signaling cascades such as the 
PI3K/Akt/mTOR pathway, which plays an important role in promoting the stemness 
of prostate CSCs, have been demonstrated in both pre-clinical and clinical studies as 
a potential therapeutic target for the treatment of advanced prosetate cancer (as 
discussed in the published review article in Chapter 2). Furthermore, celluar 
components (e.g. osteoblasts and adipocytes) within the bone marrow have also been 
suggested to contribute to a CSC niche and as a result promote cancer development 
and progression [22, 23, 29]. Nevertheless, the exact roles and mechanisms of these 
cellsin promoting the homing and colonization of prostate CSCs into the bone 
marrow during prostate tumor metastasis is still far from clear.  
 
Ang-1 is one of the osteoblast-secreted paracrines that was found to play an 
important role in regulating HSC stemness and quiescence [30]. As described in 
Chapter 3, I have uncovered a key role of Ang-1/Tie-2 in supporting the homing of 
prostate CSCs into the bone marrow. This work has been accepted for publication by 
the journal Oncotarget. 
 
In Chapter 4, I have used a novel 3D spheroid co-culture model to help identify the 
role and underlying mechanism of action of adipocytes in promoting prostate CSCs 
self-renewal. This work will be submitted as a research article shortly. 
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Chapter 2: Literature Review 
2.1 CSC in the development and progression of prostate cancer  
2.1.1 Anatomy of the human prostate 
 
Figure 2.1: Anatomy of the human prostate. Schematic of the cellular 
architecture of the human prostate (taken from [31]). 
 
There are different cell types within normal and mature prostatic epithelium: luminal, 
basal and neuro-endocrine (Figure 2.1). There is an intermediate cell type within the 
normal prostate which shares the properties of both basal and luminal cells. The 
luminal cells constitute the exocrine portion of the prostate which secretes prostatic 
acid phosphatase (PAP) and prostate specific antigen (PSA) into glandular lumina. 
They are dependent on androgens for their survival and hence, they express high 
levels of androgen receptor (AR). Besides that, basal cells reside as one or two layers 
connected to the basement membrane below the luminal cells. Unlike luminal cells, 
basal cells express a low level of AR and also exclusively express p63 (a homolog of 
the tumor suppressor gene p53). Hence, luminal and basal cells can be differentiated 
by different markers. Luminal cells express cytokeratins (CKs) CK8 and CK18, 
whereas, basal cells express CK5 and CK14, but not CK8 or CK18. Besides that, 
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intermediate cells express CKs of both basal and luminal cells (CKs 5, 14, 8, and 18) 
[3, 31].  Neuroendocrine cells are considered as rare cells which are often located in 
the luminal layer of the epithelium and is found to regulate the growth of prostate 
and development through endocrine–paracrine actions. Serotonin and thyroid-
stimulating hormone can be found in the major types of neuro-endocrine cell. They 
are terminally differentiated, post-mitotic cell types that are androgen-insensitive.
 
Fibroblasts, myofibroblasts, and smooth muscle cells are the stromal cells that found 
in prostate which support the growth and differentiation of the epithelium. Blood cell 
elements like vascular and stromal endothelial cells are also present in the gland [32].  
2.1.2 Localization of stem cells in the prostate 
Currently, the three proposed models of stem cell differentiation in normal tissue 
include the linear, bidirectional, and independent lineages. 
2.1.2.1 Linear differentiation model 
Biologically, basal cells contain many characteristics of stem cells including their 
relatively undifferentiated state, high proliferative capacity, resistance to apoptosis, 
and a long life span [33]. This linear model is defined by Isaacs & Coffey [34], 
where stem cells within the basal cell will undergo asymmetric cell division and give 
rise to one stem cell copy (self-renewal) and one multipotent progenitor cell (or 
transient amplifying cell). There are several types of marker that have been used to 
identify the prostate stem cells in the basal cell population: stem cell antigen-1 (Sca-
1, also known as Ly6a), ALDH, CD133 (Prom1), Trop-2, and CD44. However, as 
reported by previous studies, most non-stem cells in prostate mouse model also 
express these markers. Leong et al. [35] identified CD117 as a new marker of a rare 
adult mouse prostatic stem cell population, CD117+ cells are predominantly basal 
 Dissecting the prostate cancer  stem cell niche inside the bone marrow. 25
(CK14+) in the mouse and exclusively basal (p63+) in the human. This new marker 
is then combined with other stem cell markers which define a sub-population of cells 
as Lin-Sca-1+CD133+CD44+CD117+ which are capable of regenerating prostatic 
epithelium that consists of all epithelial cell types in vivo. Some studies also used 
Alpha 2 Beta 1 integrin (α2β1 High) CD44+CD133+ and Trop2 and CD49f as the 
markers to define the human prostate stem cells, which are found in the basal 
epithelium [36]. 
2.1.2.2 Bidirectional differentiation model 
Wang et al. and Kurita et al. proposed that CK5+8- basal cells are the ‘only’ source 
of prostatic stem cells, and indicated the possible existence of a distinct multipotent 
stem cell in the intermediate cell population [37, 38]. 
2.1.2.3 Independent lineages model 
Linear and Independent models postulate that stem cells are confined to a single-cell 
type, either basal or intermediate cell. However, according to Wang et al., stem cells 
may also be presented in the luminal compartment of the prostate gland [39]. They 
used the Nkx3-1 homeobox gene expression to identify the stem or progenitor cell in 
the luminal compartment. Meanwhile, the rare luminal cells that express Nkx3-1 in 
the absence of testicular androgens or known as castrate-resistant Nkx3-1-expressing 
cells, CARNs are shown to be bi-potent and maintain the capacity to self-renew in 
vivo thus proving the presence of stem cells in the prostate gland [31]. 
Based on these three models, it appears that at least three major sites normally 
contain prostate stem cells. Nevertheless, whether the stem cells in these three 
different sites all contribute to the development of disease such as cancer or whether 
they were susceptible to the same genetic instability remains unclear.  
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2.1.3 Origin of prostate CSCs 
Prostate cancer most probably arises from the luminal cells because the bulk 
population of tumour cells express luminal cell-specific markers (CK 8, CK 18, AR, 
PSA and PAP), but lack the expression of basal cell markers, such as p63. Some 
studies also suggested that this disease arises from the intermediate progenitors 
which can undergo self-renewal [32]. On the other hand, Liu and colleagues 
observed that most primary tumors consist of luminal cells, whereas the majority of 
metastases contain basal cells [40]. Recently, the expression of  prostate epithelial 
stem cell markers in patients with primary and metastatic prostate cancer has been 
examined, with the result showing that approximately 0.1% of tumor cells express 
this phenotype (n > 40) [3]. There are two main types of prostate CSC markers that 
had been identified in recent years. These include prostate CSC surface markers: 
CD338, CD57, CD44, CD26 (Dipeptidyl peptidase I), CD133, CD13, CD104 
(integrin b 4 ,) CD10,  CD138 ( syndecan ), CD38, α2β1, Her-2/New and Sca-1. The 
other types of markers are responsible for supporting the renewal of prostate CSC. 
These included BrdU, Ki67, Bmi-1, beta-catenin and BCL-2 [41, 42].  
 
2.1.4 Regulation of prostate CSCs  self-renewal 
There are several critical signaling pathways that play an important role in the 
regulation of prostate CSC self-renewal including hedgehog (Hh), Wnt, Notch and 
phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR [43, 44]. The Hh pathway regulates 
adult stem cell quiescence and self-renewal. It induces the expression of a polycomb 
gene, Bmi-1, which is expressed at high levels in the prostate cancer cell lines. The 
Hh pathway has been shown to suppress the expression of p16INK4A and p14ARF 
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while enhancing the expression of human telomerase reverse transcriptase (hTERT) 
[45]. The Wnt pathway promotes self-renewal, proliferation and transient 
differentiation of normal stem cells and is involved in vertebrate limb development 
and regeneration [10, 46-48]. Based on a previous study, Wnt signaling has been 
shown to be active in prostate CSCs, and Bisson and Prowse [49] showed that 
modulation of the activity of beta-catenin, a downstream effector of Wnt, alters CSC 
properties as reflected by the changes in the sphere-forming capacity of prostate 
cancer cells. Notch signaling promotes the survival and proliferation of normal 
neural stem cells and inhibits differentiation. Furthermore, previous studies have also 
shown that the Notch pathway promotes prostate cancer development [50, 51]. 
Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a tumor 
suppressor gene that helps to maintain stem cells in a quiescent state through 
suppression of the PI3K/Akt/mTOR pathway. PTEN also served as a negative 
regulator of both mTOR and STAT3. According to Wang et al. [52], deletion or 
mutation of PTEN has been reported to induce CSC development, which may be 
mediated by aberrant activation of the PI3K/Akt/mTOR pathway.  
Recently, the effect of single or dual inhibitors of the PI3K/Akt/mTOR pathway 
against prostate cancer has been studied intensively. The following review article 
(published in Current Medicine Chemistry) summarized the key evidence from both 
pre-clinical and clinical studies which support the therapeutic value of targeting the 
PI3K/Akt/mTOR pathway. 
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2.1.5 Abstract 
The phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR pathway is one of the most 
frequently activated signaling pathways in prostate cancer cells, and loss of the tumor 
suppressor PTEN and amplification of PIK3CA are the two most commonly detected 
mechanisms for the activation of these pathways. Aberrant activation of 
PI3K/Akt/mTOR has been implicated not only in the survival and metastasis of 
prostate cancer cells but also in the development of drug resistance. As such, 
selective inactivation of this pathway may provide opportunities to attack prostate 
cancer from all fronts. However, while preclinical studies examining specific 
inhibitors of PI3K or mTOR have yielded promising results, the evidence from 
clinical trials is less convincing. Emerging evidence from the analyses of some solid 
tumors suggests that a class of dual PI3K/mTOR inhibitors, which bind to and 
inactivate both PI3K and mTOR, may achieve better anti-cancer outcomes. In this 
review, we will summarize the mechanisms of action of these inhibitors, their 
effectiveness when used alone or in combination with other chemotherapeutic 
compounds, and their potential to serve as the next generation therapies for prostate 
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2.1.6 Introduction 
Prostate cancer is the most common type of solid tumor in men around the world and 
is a leading cause of morbidity and mortality [31]. When diagnosed at an advanced 
stage at which surgery is no longer feasible, the only frontline treatment available for 
prostate cancer is hormone ablation therapy. Unfortunately, the majority of patients 
will eventually relapse and develop castration-resistant prostate cancer (CRPC), a 
fatal and terminal stage that is regarded as incurable. Prostate cancer frequently 
develops resistance to conventional chemotherapy, with the most effective treatment 
(Docetaxel, a microtubule-disrupting agent) extending patient survival for an average 
of only two months and is associated with significant side effects [53]. Thus, there is 
an urgent need for a better therapy for CRPC that shows improved treatment efficacy 
and minimal side effects.  
 
Phosphatidylinositol 3-kinase (PI3K) belongs to a family of lipid kinases responsible 
for phsophorylating phosphatidylinositol within the cell membrane (Figure 2.4). It 
regulates a wide range of cellular functions such as metabolism, proliferation, 
survival and motility [53, 54] . The PI3K are grouped into three different classes 
(Class I-III) based on their functional and structural features. Aberrant activation of 
PI3K, particularly members of class IA, is commonly detected in various types of 
cancer. In prostate cancer, deregulation of PI3K and its downstream targets has been 
linked to tumor growth, angiogenesis and metastasis as well as the development of 
drug resistance, making PI3K a potential therapeutic target for improving the 
treatment of advanced prostate cancer patients. Over the past decade, a number of 
PI3K inhibitors have been under clinical development, with dual PI3K/mTOR 
inhibitors such as NVP-BEZ235 and PI103 currently in the spotlight due to their 
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successful application in many pre-clinical studies [55, 56]. In this review, we 
describe the rationale for targeting PI3K with dual PI3K/mTOR inhibitors in the 
treatment of prostate cancer and the safety issues that must be overcome before these 
compounds can eventually be brought to the clinic.  
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Figure 2.2: The PI3K/Akt/mTOR pathway. Phosphatidylinositol 3-kinase (PI3K) 
is activated when growth factors bind to receptor tyrosine kinases (RTKs, such as 
epidermal growth factor receptor (EGFR), insulin-like growth factor receptor 
(IGFR), and platelet-derived growth factor receptor (PDGFR). G protein-coupled 
receptors (GPCRs) can also cause activation of PI3K. These events promote the 
conversion of phosphatidylinositol-4,5-bis phosphate (PIP2) into 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) and the subsequent activation of Akt. 
Akt activation elicits a broad range of downstream signaling events to regulate 
cellular processes, which include the phosphorylation of nuclear factor-κB (NF-κB), 
murine double minute (MDM2), tuberous sclerosis complex 2 (TSC2) and 
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mammalian target of rapamycin (mTOR).  Besides that, mutation of the tumor 
suppressor PTEN, which is commonly detected in prostate cancer, also contributes to 
aberrant Akt activation in cancer cells. 
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2.1.7 The PI3K/Akt/mTOR Signalling Cascade 
PI3Ks. There are three classes of PI3K which can be grouped according to their 
functional and structural characteristics. Class I PI3Ks are the best-studied members 
of the PI3K family. These kinases are composed of a 110 kDa catalytic subunit 
(p110) and an 85 kDa regulatory subunit (p85). Depending on the composition of the 
heterodimer, class I PI3Ks can be further divided into subclass 1A (p110α, p110β 
and p110δ) or 1B (p110γ) [57, 58].  Class I PI3Ks are mainly activated through the 
p85 subunit, which binds to the phosphotyrosine residue of the ligand-activated 
receptor tyrosine kinases (RTKs) [59], although a previous study demonstrated that 
p85 also exerts inhibitory effects on p110 [60]. Among the RTKs, epidermal growth 
factor receptor (EGFR), insulin-like growth factor receptor (IGFR) and platelet-
derived growth factor receptor (PDGFR) have all been shown to activate PI3K [61-
63]. Additionally, both Ras and G protein-coupled receptors have been found to bind 
to p110 and activate PI3K activity [61, 64]. Once activated, the p110 catalytic 
subunit will convert phosphatidylinositol‑4,5‑bis phosphate (PIP2) at the membrane 
into phosphatidylinositol‑3,4,5‑trisphosphate (PIP3) by phosphorylating the 3’OH 
position [61]. PIP3 provides docking sites for signaling proteins by recruiting two 
pleckstrin homology (PH) domains: a putative 3‑phosphoinositide‑dependent kinase 
1 (PDPK1) and the serine–threonine protein kinase Akt (also known as protein 
kinase B) to the cell membrane, where Akt is phosphorylated and activated by 
PDPK1 [62, 63]. This process is inhibited by the tumor suppressor PTEN, which 
promotes the conversion of PIP3 into PIP2, thus inactivating the PI3K pathway [62]. 
 
The class IB PI3Ks consist of catalytic subunit p110γ and the regulatory subunit p10; 
which are activated directly by G-protein coupled receptors through interaction of its 
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regulatory subunit with the Gβγ subunit of trimeric G proteins [61, 65, 66]. Class II 
PI3Ks are monomeric catalytic subunits which preferentially use 
phosphatidylinositol‑4‑phosphate (PI4P) as substrates [67, 68]. There are currently 
three class II isoforms being identified: PI3KC2α, PI3KC2β and PI3KC2γ. PI3KC2α 
and PI3KC2β are almost ubiquitously expressed; while PI3KC2γ are restricted to 
liver, pancreas and prostate [69, 70]. Class III PI3K are heterodimeric enzymes 
composed of adaptor (p150) and a single catalytic subunit, VPS34 (homologue of the 
yeast vacuolar protein sorting-associated protein 34, also known as PI3KC3 
[61].VPS34 produces phosphatidylinositol‑3‑phosphate (PI3P) which takes part in 
membrane trafficking [67]. Besides that, it has been implicated in regulating the cell 
growth and autophagy [61, 71]. Intriguingly, it also plays an important role in 
cellular stress response [71].  
 
Akt. Akt is a serine/threonine kinase that plays a major role in cell survival. 
Activation of Akt elicits a broad range of downstream signaling events by 
phosphorylating a number of substrates, which include BclxL/Bcl-2-associated death 
promoter (BAD), forkhead box O1 (FOXO1) family transcription factors, nuclear 
factor‑κB (NF‑κB), murine double minute (MDM2), glycogen synthase kinase 3β 
(GSK3β), tuberous sclerosis complex 2 (TSC2), ribosomal protein S6 kinase (S6K) 
and mammalian target of rapamycin (mTOR). [61, 62]. Phosphorylation of the pro-
apoptotic protein BAD and FOXO1 by Akt leads to inhibition of their function, thus 
protecting the cell from apoptosis [61, 72-74]. In addition, Akt activation antagonizes 
p53-mediated apoptosis by inducing the phosphorylation of MDM2, which 
ultimately leads to destabilization of the p53 protein [75]. Akt also negatively 
regulates GSK3β, thereby reducing glucose metabolism and cell cycle progression 
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[76]. Phosphorylation of TSC2 by Akt inhibits the rheb GTPase activity of 
TSC1/TSC2 dimers. As a result, rheb is activated and stimulates the downstream 
mTOR pathway. 
 
mTOR. There are two distinct mTOR complexes: mTORC1 (mTOR Complex-1) and 
mTORC2 (mTOR Complex-2). mTORC1 consists of the mTOR catalytic subunit, 
Raptor (regulatory-associated protein of mTOR), PRAS40 (proline-rich Akt substrate 
40 kDa) and the mLST8/GbL protein [57, 77]. The best characterized effectors 
downstream of mTORC1 involve phosphorylation of the ribosomal protein p70S6K 
(or S6K1) and 4EBP1 (also known as Phosphorylated Heat-stable and Acid-Stable 
protein, PHAS1). Both of these effectors take part in regulating mRNA translation 
[61, 78-80]. S6K1 is a serine/threonine kinase that phosphorylates and activates the 
40S ribosomal S6 protein and facilitates the recruitment of the 40S ribosomal subunit 
to actively translating polysomes [78, 79, 81]. Additionally, S6K1 kinase can act as a 
negative regulator that phosphorylates and inhibits the adaptor protein insulin 
receptor substrate 1, thereby inhibiting insulin or insulin like growth factor 1 and 
causing inactivation of the PI3K pathway [63]. On the other hand, 4EBP1 is a low 
molecular weight protein that plays a role in mRNA translation. Phosphorylation of 
4EBP1 by mTORC1 reduces the affinity of 4EBP1 for eIF4E (eukaryotic Initiation 
Factor-4E). As a result, eIF4E associates with eIF4G (Eukaryotic Translation 
Initiation Factor-4-Gamma), the adenosine triphosphate-dependent RNA helicase 
eIF4A (Eukaryotic Translation Initiation Factor-4A), and eIF4B (Eukaryotic 
Translation Initiation Factor-4B) to form an active complex. This complex then binds 
to 5'-capped mRNAs and initiates mRNA translation [78-80]. 
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mTORC2 consists of mTOR, Rictor (rapamycin-insensitive companion of mTOR), 
mSIN1 (mammalian stress-activated protein kinase-interacting protein 1) and 
mLST8/GbL [61, 82, 83]. Unlike mTORC1, mTORC2 can be phosphorylated or 
activated in the absence of Rheb. However, its activation requires PI3K and the 
TSC1/TSC2 complex [84]. When the mTORC2 complex binds to Rictor, it can 
facilitate the function of PDK1, which phosphorylates Akt on Ser 473 and Thr 308. It 
also plays a role in cytoskeleton organization by regulating actin polymerization and 
the activation of Ras homolog gene family, member A (RhoA) and Ras-related C3 
botulinum toxin substrate 1 (Rac1) [84, 85]. 
 
2.1.8 Aberrant activation of PI3K/Akt/mTOR in prostate cancer  
2.4.4.1 Genetic inactivation of PTEN 
Impaired negative regulatory feedback of the PI3K pathway caused by genetic 
alterations is one of the major mechanisms underlying cancer development [63]. 
PTEN, a negative regulator of the PI3K/Akt/mTOR pathway, is subjected to several 
different types of genetic alterations that are commonly found in prostate cancer. For 
an instance, PTEN mutations, which include both germline and somatic mutations, 
occur at a frequency of up to 50% in prostate cancer [61, 86-90]. Deletion of the 
PTEN gene on chromosome 10q23 is commonly observed in prostate cancer [91, 
92]. Inactivation of PTEN via homozygous and hemizygous deletion has been 
reported to correlate with the Gleason score, presence of lymph node metastasis, 
development of hormone-refractory disease and the presence of the ERG gene fusion 
in prostate cancer [73, 86].  On the other hand, somatic PTEN mutations have been 
detected in both localized and metastatic protate cancer tissues in at least one 
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metastatic site [93]. The missense mutation P95S in exon 5, D223N in exon 7 or 
deletion of an adenine leading to a premature stop codon in amino acid 164 (exon 5) 
of the PTEN gene have also been reported [94]. The combination of somatic 
mutations, LOH and decreased expression due to methylation of the PTEN gene 
displays a high frequency in prostate tumors [65]. 
 
2.4.4.2 PIK3CA mutation/amplification 
Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha isoform 
(PI3KCA) is encoded by the PIK3CA oncogene and catalyzes the production of 
phosphatidylinositol-3, 4, 5-triphosphate (PIP3), resulting in the activation of 
downstream Akt signaling. Somatic mutation and amplification of the gene encoding 
the catalytic subunit of PI3KCA are the two most frequent genetic alterations 
observed in PI3KCA. A variety of human tumors, including breast, colon, 
endometrial and prostate cancer, have been reported to harbor these genetic 
alterations [74, 95]. Genetic analyses of prostate cancer have demonstrated that the 
PI3KCA mutation occurs in approximately 5% of patients; while the increase in copy 
number can be detected in up to 10% of  patients [86, 88, 96]. 
The missense mutations E545K and H1047R, in exons 9 and 20, corresponding to the 
helical and kinase domains of p110α, respectively, are two “hotspot” mutations 
clustered in PI3KCA. These somatic mutations have been shown to mediate aberrant 
Akt activation by enhancing the levels of PIP3, thus leading to cellular 
transformation [61, 63]. On the other hand, amplification of PI3KCA has been 
reported during the progression from hormone-dependent to hormone-refractory 
prostate cancer and was found to correlate with Gleason score in human prostate 
tumors [15]. Another comprehensive study based on direct sequencing, 
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pyrosequencing, quantitative mRNA analysis and fluorescence in situ hybridization 
performed in over 100 prostate tumors also revealed an association of high-grade 
prostate tumors with PIK3CA mRNA overexpression, resulting in activation of the 
PI3K signaling pathway and increased pAkt protein expression [97]. 
 
2.1.9 Role of PI3K/Akt/mTOR in the development and progression of prostate 
cancer 
2.4.5.1 Tumor initiation 
The PI3K/Akt/mTOR signaling pathway, which is activated via different 
mechanisms in human cancers, plays critical roles in tumor initiation and disease 
progression. Alterations in key players in this pathway have been reported in 
malignant prostate cancer and are associated with increasing tumor stage, grade, and 
the risk of biochemical recurrence [98]. Specifically, loss of PTEN function and 
genetic alterations of PI3KCA are common mechanisms resulting in changes in the 
PI3K/Akt/mTOR signaling pathway in cancer cells. Loss of PTEN function is known 
to downregulate cell cycle inhibitors such as p27, p18ink4c and p14arf, whereas it 
activates key components of the PI3K/Akt/mTOR signaling pathway, such as Akt, 
Rheb and TSC2. Overall, PTEN inactivation promotes cancer cell invasiveness, 
proliferation, angiogenesis and drug resistance during prostate cancer development 
[99].  Activation of the mTOR pathway due to the loss of PTEN also results in 
overexpression of the eIF4E and S6K1 proteins, which have both been linked to 
prostate cancer progression [100]. Loss of PTEN function also leads to increased 
eIF4E phosphorylation via activation of the PI3K/Akt/mTOR signaling pathway 
[101]. Knockdown of PTEN in a transgenic mouse model was found to induce tumor 
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invasion through eIF4E phosphorylation [101]. Another study verified the important 
role of eIE4F in a prostate cancer model via the expression of a non-
phosphorylatable form of eIF4E in knock-in mice, which became resistant to 
tumorigenesis induced by PTEN knockout [101]. The non-phosphorylatable form of 
eIF4E was also shown to be associated with decreases in the levels of the MMP3, 
CCL2, VEGFC, BIRC2 and NFKBIA (IκBα) proteins, which have been implicated 
in prostate cancer [101]. Additionally, PI3K3CA mutation or amplification has been 
reported to promote prostate tumorigenesis both in vitro and in vivo. PI3KCB, which 
is the second class of PI3K isoform, has also been found to play roles in the 
development of prostate cancer [102]. 
 
2.4.5.2 Tumor metastasis 
Tumor metastasis occurs when a tumor cell invades into the surrounding tissues 
through the production of a series of proteases, leading to the degradation of the 
extracellular matrix (ECM) and the dissemination of tumor cells into the circulation. 
This phenomenon is believed to involve a process known as epithelial-to-
mesenchymal transition (EMT), where tumor cells acquire a mesenchymal 
phenotype to become more mobile and invasive [103]. The PI3K/Akt/mTOR 
signaling pathway has been shown to activate a variety of proteases that may take 
part in cell invasion and migration. For example, urokinase plasminogen activator-1 
is an important protease involved in degrading plasminogen in the ECM and is 
activated by PI3K [104]. Other proteases downstream of PI3K include matrix-
metalloproteinase 9 (MMP-9), which degrades collagen IV, and matrix-
metalloproteinase 1 (MMP-1), which drives cell division, motility, and invasion, as 
well as matrix-metalloproteinase 3 (MMP-3), which triggers EMT [105, 106]. 
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Further evidence supporting the role of PI3K signaling in prostate tumor metastasis 
comes from a study by Mulholland et al., which demonstrated the cooperation of 
RAS/MAPK activation with the PTEN inactivation during prostate cancer 
progression. Crossing mice carrying a K-ras mutation with PTEN-null mice resulted 
in frequent macrometastasis with 100% penetrance, which was associated with the 
induction of EMT [107]. 
 
2.4.5.3 Cancer stem cell (CSC) survival 
Recent evidence supports the existence of prostate CSCs, which are likely to arise 
from normal stem cells located in the basal, intermediate or luminal compartment of 
prostate gland [108]. PTEN has long been suggested to regulate hematopoietic stem 
cell renewal. Recent studies have demonstrated that it may play a similar role in the 
maintenance of CSCs. Deregulation of the PI3K/Akt/mTOR signaling pathway 
caused by PTEN inactivation was found to promote CSC properties in a variety of 
solid tumors, including glioblastomas, hepatocellular carcinomas, breast carcinomas, 
lung adenocarcinomas, and prostate carcinomas [84]. Deletion of PTEN in luminal 
cells expressing Nkx3.1 (a stem cell marker regulating prostate epithelial 
differentiation) results in rapid tumor development [109]. Moreover, the loss of 
PTEN negatively regulates p63
+
 prostatic basal cell proliferation, without blocking 
differentiation, causing the expansion of a prostate stem/progenitor-like 
subpopulation [110-112]. Dubrovska et al. also reported that PTEN knockdown in 
DU145 cells increases their sphere-forming ability, supporting the inhibitory 
function of PTEN in prostate CSC self-renewal [113].  
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2.4.5.4 Development of therapeutic resistance 
The PI3K/Akt/mTOR signaling pathway also plays a significant role in promoting 
drug resistance [84]. West et al. demonstrated that loss of PTEN was strongly 
associated with a poor prognosis and chemoresistance in a number of types of cancer 
[99, 114]. Meanwhile, the restoration of PTEN expression or suppression of Akt 
phosphorylation restored the doxorubicin sensitivity of doxorubicin-resistant PC3 
cells [115]. Interestingly, the effect of the PI3K/Akt/mTOR pathway on drug 
resistance appears to be related to its functional role in CSC maintenance. A study by 





 prostate cancer progenitor cells [116]. Meanwhile, 
combining a PI3K-mTOR inhibitor with the chemotherapeutic drug Taxotere was 
found to reduce the CSC population in human prostate cancer models. Surprisingly, 
cancer progenitor cells carrying a PTEN missense mutation (E91D) repopulated after 
the combined treatment, further highlights the importance of the PI3K/Akt/mTOR 
pathway in maintaining the survival of CSCs under chemotherapy [116]. 
 
2.4.5.5 Development of castration-resistant prostate cancer 
The PI3K/Akt/mTOR signaling pathway has been found to be critical for 
maintaining the growth and proliferation of prostate cancer cells under low-androgen 
conditions [117]. Moreover, preclinical studies have suggested that loss of PTEN 
function, which activates the PI3K/Akt/mTOR signaling pathway, may result in 
androgen-independent prostate cancer [118]. For example, prostate tumors formed in 
prostate-specific PTEN knockout mice initially respond to androgen ablation, as 
demonstrated by tumor regression. However, the tumor cells were found to continue 
to propagate under androgen-deprived conditions [98, 119]. Additionally, the 
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progression of an androgen-dependent prostate cancer cell line to androgen 
independency after long-term culturing under androgen-deprived conditions was 
found to lead to resistance to PI3K/Akt inhibition [120]. These findings suggest that 
aberrant activation of the PI3K/Akt/mTOR signaling pathway may play a crucial role 
in maintaining the survival of prostate cancer cells during the development of CRPC.  
 
2.1.10 DUAL INHIBITORS OF PI3K/AKT/MTOR FOR THE TREATMENT 
OF PROSTATE CANCER 
2.4.6.1 Mechanisms of action 
Over the past decade, numerous synthetic inhibitors have been developed to target 
different layers of the PI3K/Akt/mTOR pathway (Figure 2.5) [63]. These agents 
exhibit different degrees of suppression of cell proliferation, survival, motility and 
angiogenesis as well as metastasis [121]. Based on their general action, these 
inhibitors can be categorized into four different types: dual PI3K–mTOR inhibitors, 
PI3K inhibitors (not targeting mTOR), Akt inhibitors and mTOR inhibitors. In this 
review, we will focus on dual PI3K-mTOR inhibitors, as they have recently been 
recognized as an essential strategy for maximizing the inhibition of the 
PI3K/Akt/mTOR pathway [121, 122]. These inhibitors take advantage of the 
structural similarity between the PI3K subunit p110α and mTOR (both belong to the 
phosphatidylinositol kinase–related kinase family), which allows them to inhibit 
PI3K mTOR activities simultaneously [63, 123]. The efficacy of some of these 
inhibitors in the treatment of prostate cancer is currently being evaluated under pre-
clinical and clinical settings (As summarized in Table 2.1), which merits detailed 
discussion in the following sections. 
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Figure 2.3: Targeting of dual PI3K-mTOR inhibitors in the PI3K/Akt/mTOR 
pathway. Dual PI3K-mTOR inhibitors target both PI3K and mTOR (mTORC1 and 
mTORC2) and, thus, have the potential of achieving better clinical effect against 
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LY294002 was one of the first few dual inhibitors to be described and is currently 
the most studied [124-126]. LY294002 was shown to suppress the invasion of 
prostate cancer cells through downregulation of HIF1-α and VEGF [127]. In 
addition, treatment with LY294002 was also found to sensitize prostate cancer cells 
to radiation-induced apoptosis [128]. Renner et al. were the first research group to 
utilize a transgenic model to study the effect of LY294002 in prostate cancer. They 
expressed a constitutively active form of the p110-alpha subunit in the epithelial cells 
of the prostate. The phosphorylation of Akt and eIF4G as well as the elevation of the 
Mst1 and RanBP2 protein levels were all found to be inhibited by LY294002 
treatment in vivo [100]. LY294002 has been extensively tested in different 
preclinical studies. However, despite its effectiveness in animal models, this 
compound has failed to function efficiently in patients, possibly due to non-specific 
effects against non-PI3K kinases [63]. 
 
SF1126 is a prodrug developed commercially through modifying LY294002 via 
conjugation with an RGD (arg-gly-asp) tetra-peptide. This modification not only 
enhanced the solubility of the compound, but also improved its effect in targeting 
tumor vasculature [129]. In preclinical studies, administration of SF1126 was shown 
to inhibit the growth and angiogenesis of prostate tumors in vivo, but with lower 
toxicity compared to LY294002 [61, 129]. Reverse-phase protein array analysis 
revealed downregulation of Akt, S61 kinase and p27 levels following SF1126 
treatment, indicating that the compound represses the PI3K/Akt/mTOR pathway and 
leads to tumor suppression [130]. In a phase I study addressing solid and B cell 
malignancies, SF1126 was found to inhibit Akt phosphorylation and induce 
apoptosis of the cancer cells in vivo [131]. The compound was also well tolerated by 
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the patients, which indicates that it warrants further investigation in additional 
clinical trials.  
 
NVP-BEZ235 is an imidazaoquinazoline derivative that binds to ATP-binding 
pockets, thus inhibiting PDK1, PI3K isoforms and mTOR kinase. NVP-BEZ235 was 
found to reduce Akt phosphorylation and increase FOXO3a nuclear localization and 
transcriptional activity. The efficacy of NVP-BEZ235 against the CSC population 
was compared with that of different conventional drugs, including Taxotere, 
fluorouracil and Oxaliplatin, and was found to be the most effective agent in 
targeting CSCs [116]. Preclinical data also demonstrated that NVP-BEZ235 
possesses strong anti-proliferative activity against tumor xenografts displaying a loss 
of PTEN or harboring a gain-of function-PI3K mutation [61]. Additionally, a recent 
study showed that the combination of NVP-BEZ235 with the chemotherapy drug 
Taxotere suppressed the tumor growth in vivo through targeting of prostate cancer 
progenitor cells [116]. Currently, this compound is being tested in a Phase Ib clinical 
trial together with Abiraterone (an FDA-approved compound that inhibits androgen 
production) in patients with CRPC.  
 
XL765 is a potent inhibitor of Class I PI3K isoforms and mTOR that is available for 
oral administration for the treatment of solid tumors.  A preclinical study 
demonstrated its ability to inhibit all class I isoforms of PI3K and mTOR, leading to 
inhibition of the growth of tumors generated from breast, lung, ovarian and prostate 
cancer [129]. However, a phase I study showed that XL765 was ineffective in 
patients with metastatic or unresectable solid tumors. 
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GDC0941 acts through inhibition of the class I PI3Ks and mTOR, and its anti-cancer 
effect has been demonstrated in pre-clinical xenograft tumor models. GDC0941 is 
currently undergoing a Phase I trial in patients with locally advanced or metastatic 
solid tumors. In vitro and in vivo investigations have suggested that GDC0941 is 
effective against prostate cancer when it is administered in combination with the 
allosteric mTOR inhibitors rapamycin and RAD001 [122]. 
 
Fisetin (3,7,30,40-tetrahydroxyflavone) belongs to the flavonol subgroup of 
flavonoids along with quercetin, myricetin and kaempferol. It can be found in a 
variety of fruits and vegetables, including strawberry, apple, persimmon, kiwi, 
cucumber and onion. Fisetin has been studied for many years and is known to exhibit 
diverse biological properties, ranging from antibacterial to cancer therapeutic effect. 
This compound was recently redefined as a dual PI3K/mTOR inhibitor that targets 
not only the mTOR signaling pathway, but also Akt phosphorylation. Haddad et al. 
compared the effect of two flavonoids, 2,20- dihydroxychalcone (DHC) and fisetin, 
in prostate cancer cells. The results demonstrated that these two compounds were 
able to induce apoptosis and decrease the clonogenic survival of prostate cancer cells 
[132].  Another study revealed a similar result, showing that fisetin was able to 
decrease the viability of hormone-dependent prostate cancer cells, but not that of 
normal prostate epithelial cells [133]. Treatment of PC-3 cells with fisetin had 
inhibitory effects on mTOR targets including S6, eIF4B and 4EBP1, which led to 
autophagic-programmed cell death [134, 135].  
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2.4.6.2 Pharmacokinetic/pharmodynamic studies 
Among the known dual PI3K/mTOR inhibitors, LY294002 appears to be the most 
toxic, as shown in several in vivo studies. Two out of 12 animals died after receiving 
2 mg of LY294002 due to either obstruction of the small bowel or unknown causes 
[136]. Moreover, approximately 80% of the animals were found to develop dry scaly 
skin that was a reversible following cessation of LY294002 treatment. Although, 
some studies did not note any toxicity associated with LY294002 or mortality of 
mice when treated with LY294002, side effects such as respiratory depression after 
injecting 2 mg of LY294002 into mice have been reported [137].  
PI3K/mTOR inhibitors with reduced side effects in patients are urgently needed to 
cure patients suffering from prostate and other solid tumors. SF1126 is a modified 
form of LY294002 that has been developed that shows reduced side effects in 
patients. The SF1126 prodrug has been tested in a phase I clinical trial. SF1126 was 
administered twice weekly to patients who presenting with stable disease for more 
than 8 weeks. Pharmacodynamic evaluation revealed that the tolerable dosage was 
up to 630 mg/m
2
. Apart from transient grade 3 diarrhea, no consistent effects on 
blood glucose levels were detected, but disease stabilization was observed in some 
patients [58].  
 
2.1.11 Conclusions 
The PI3K/Akt/mTOR signaling pathway plays a critical role in the development and 
progression of human prostate cancer. Extensive in vitro and in vivo studies have 
revealed that PI3K/Akt/mTOR is aberrantly activated either through the loss of 
PTEN function or genetic alteration of PI3KCA. These studies have provided a 
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strong basis for the development of targeted therapies against this signaling pathway. 
Currently, a number of dual PI3K/Akt/mTOR inhibitors are being study extensively 
in phase I/II clinical trials, with a few demonstrating promising anti-cancer effects 
while showing reduced side effects compared to the earlier generation of PI3K 
inhibitors. Strikingly, combinations of dual PI3K/mTOR inhibitors with current 
chemotherapeutic agents tend to display improved efficacy compared to the use of a 
single agent alone. Further pharmacokinetic/pharmodynamic studies may provide 
additional support for the development of dual PI3K/mTOR inhibitors for use as new 
treatments for management of prostate and other solid tumors. 
 
2.1.12 Role of CSCs in the development of bone metastasis 
EMT is believed to be the key event during cancer metastasis. EMT is a process in 
which epithelial cells with regular cell-cell junctions and adhesions convert into 
motile and invasive cells with mesenchymal phenotypes [10, 138]. Recent studies 
have reported a close relationship between CSCs and EMT [11, 139]. For example, 
Sampieru and Fodde [11] have shown that differentiated cancer cells acquired the 
CSC phenotype upon induction of an EMT. Other studies have demonstrated that 
growth factors released from the bone microenvironment may induce an EMT and 
cooperate via the Wnt-signaling pathway to promote the invasion of CSCs, which 
may lead to the development of bone metastasis [40, 103]. Interestingly, CXCR4, a 
protein implicated in cellular migration and the metastatic potential of cancer cells, 
was recently shown to induce the migration of CSCs [140, 141]. CXCL12 is the 
ligand for CXCR4 and is highly expressed at sites of prostate cancer metastases 
including the lungs, bone and liver. CXCR4 is highly expressed in primary prostate 
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tumors and prostate metastases but not in normal prostate tissues [142, 143], which 
further supports its role in prostate cancer metastasis. 
 
2.2 Bone marrow stem cell niche 
2.2.1 CSC specific niche 
Most primary tumor cells enter the circulation and seed at secondary tissues during 
the formation of metastasis. In the secondary site, the primary tumor cells have to 
adapt to a new microenvironment, which normally lacks nutrients and oxygen, before 
they can redevelop as macrometastasis [5]. It is now believed that the CSCs may 
reside in a microenvironment known as the CSC niche which regulates their 
differentiation and proliferation. This niche has a complex cellular and molecular 
components which include stromal, endothelial, mesenchymal and immune cells, as 
well as the extracellular matrix (ECM) and soluble factors derived from the cellular 
component [144]. Interestingly, according to previous studies, CSCs are capable of 
creating their own cancer stem cell niche by recruiting mesenchymal stem cells 
derived from bone marrow, resulting in expansion of the CSC population within the 
primary tumor [16]. On the other hand, CSCs can also ‘hijack’ the already 
established normal stem cell niches [5]. This has been demonstrated in both human 
and mouse models for prostate and breast cancer where the cancer cells were shown 
to form micrometastases within hematopoietic stem cell (HSC) niches in the bone 
marrow by competing with the HSCs [17]. According to Shiozawa et al. [17], the 
CXCL12/CXCR4 pathway, which mediates the interaction between HSCs and the 
niche, was adopted by prostate cancer cells to gain access to the HSC niche and 
cause bone metastasis. By blocking this pathway, prostate cancer bone metastasis 
 Dissecting the prostate cancer  stem cell niche inside the bone marrow. 53
was significantly suppressed. Interestingly, while disseminated prostate cancer cells 
can be detected in the bone marrow of prostate cancer patients, bone metastasis may 
take years to develop. This may reflect the time required for the disseminated cancer 
cells to articulate a suitable tumor microenvironment before the cells can grow 
exponentially.  
2.2.2 Regulation of HSC by the stem cell niche 
 
Bone plays an extensive role in maintaining the structure and movement of our body 
[145]. As demonstrated in previous studies, MSCs that residing in the bone cavity are 
responsible for differentiating into different types of marrow stromal cell lineages, 
including obsteoblasts, adipocytes, fibroblasts, chondrocytes, myocytes and 
endothelial cells [12].  The most critical role for bone marrow is to provide a cellular 
and molecular microenvironment (i.e. the niche) to regulate HSC function. This 
includes maintaining the balance between dormancy and active self-renewal as well 
as HSC mobilization and early lineage decision [5]. Undifferentiated HSCs localize 
to the endosteal region and are closely associated with osteoblasts.  This niche 
(known as an osteoblastic niche) mediates the balance between HSC quiescence, 
self-renewal and trans-marrow migration [13]. On the other hand, a vascular niche 
composed of the endothelial cells of the bone marrow sinusoids regulates 
proliferation, differentiation and trans-endothelial migration of HSCs [146]. 
 
2.2.1.1 The Endosteal/Osteoblastic Niche 
Osteoblasts are the major cellular components of the endosteal niche, which reside 
on the bone surface at the endosteum [147]. Evidence from in vivo studies has shown 
that HSC and progenitor cells mobilize to the periphery when there is a depletion of 
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osteoblasts, supporting their role in the homing of HSC [14, 15]. Osteoblasts are 
believed to be derived from bone marrow mesenchymal progenitor cells and have 
been found to produce paracrine factors such as CXCL12, osteopontin and N-
cadherin which are involved in HSC retention and maintenance in bone marrow. 
Moreover, they also can secrete a variety of molecules such as angiopoietin-1 (Ang-
1), thrombopoietin (THPO) and membrane-bound stem cell factor (SCF) which are 
involved in maintaining the quiescence of HSCs. These paracrine  factors act through 
numerous signalling pathways (e.g. Hh, Notch and Wnt signalling pathways) to 
regulate cell cycle progression and self-renewal of HSCs [147, 148]. 
 
2.2.1.2 The Vascular Niche 
The vascular niche represents another HSC niche within the bone marrow, which is 
located in the extravascular spaces between the vascular sinuses [147]. Adhesion 
molecules such as E-selectin, P-selectin, vascular cell adhesion protein 1 (VCAM1), 
Intercellular adhesion molecule 1 (ICAM1), platelet endothelial cell adhesion 
molecule 1 (PECAM1) and vascular endothelial cadherin are all found in endothelial 
cells of the vascular niche [149]. Besides that, a population of Nestin-expressing 
cells expresses CXCL12, SCF, Ang-1, Interleukin (IL) 7, VCAM-1 and osteopontin. 
These cells can be found in the perivascular environment and are suggested to play 
an extensive role in perivascular distribution through their ability to regulate HSC 
mobilization by associating with the nerve fibers of the sympathetic nervous system 
[147]. In addition, the endothelial cells in the bone marrow also take part in 
megakaryocyte maturation and thrombopoiesis via the MPL/THPO signalling 
pathway [146]. 
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2.2.3 Ang-1/Tie2 signalling pathway in the maintenance of HSC quiescence 
Ang-1 is a pro-angiogenic protein that regulates endothelial cell proliferation and 
blood vessel formation. It has also been found to be one of the key osteoblast-
secreted paracrine factors responsible for the maintenance of HSCs [4]. It binds to 
Tie-2 receptors expressed in HSCs and activates downstream targets that include 
AKT and Bmi-1. Tie-2 belongs to the tyrosine kinase receptor family, which also 
binds to other ligands such as Ang-2, Ang-4 [49]. According to Arai et al. [30], Tie2 
receptors are expressed on the quiescent HSCs which adhere to osteoblasts that line 
the inner surface of the bone. They further demonstrated that osteoblasts secrete large 
amounts of Ang-1 which promotes the adhesion of HSCs to osteoblasts while at the 
same time maintains HSC quiescence by preventing the cells from undergoing cell 
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2.3 Adipocytes in the development and progression of prostate cancer 
2.3.1 Adipocytes  
Adipocytes also defined as lipocytes traditionally have been viewed as fat storage 
cells. When viewed microscopically, these cells appear full of triglycerides, the 
chemical form of fats that exist in food and the body. There are three types of 
adipocytes: white adipose tissues (WAT), brown adipose tissues (BAT) and yellow 
adipose tissue (YAT/marrow fat). The white lipocyte is the most abundant in the 
body which involved in fat storage; whereas, brown lipocytes produce heat. The 
marrow fat or the yellow adipose tissue (YAT) constitutes a third category of fat 
tissue and its metabolic activity is largely unknown [150]. On the other hand, they 
play an important role in regulating the endocrine and immune systems. Furthermore, 
they also help to maintain proper energy balance. Meanwhile,  adipocytes are formed 
through the process of adipogenesis (Figure 2.4). There are several cell types in 
adipose tissues; however, only one third of the tissue is constituted by adipocytes and 
the rest is represented by fibroblasts, macrophages, stromal cells, monocytes and 
preadipocytes. 
 
2.3.1.1 White Adipose Tissues (WAT) 
White adipose tissue (WAT) is a major secretory and fat storage. It plays an 
important role in cell function through regulation of a complex network of endocrine, 
paracrine, and autocrine signals, which will affect the response of different tissue 
types, including the hypothalamus and metabolic organs like the pancreas, liver, 
skeletal muscle, kidneys, adrenal glands, or the cardiovascular system.  
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2.3.1.2 Brown Adipose Tissue (BAT) 
Unlike WAT, brown adipose tissue (BAT) enables the body to release excess energy 
as heat. Brown adipose tissue (BAT) is also known as the baby fat, which mostly 
found in babies; however, it will be converted into white adipose tissues in adulthood 
by a specialized molecule called mitochondrial uncoupling protein 1 (UCP1), which 
is activated in the mitochondria by diet. Interestingly, the induction of UCP1 in white 
adipose tissues can lead to resistance in obesity development, although the exact 
mechanism is unknown. 
 
2.3.1.3 Yellow adipose tissue (YAT) 
Yellow adipose tissue is often referred as bone marrow fat. It has a yellowish 
appearance which is due to the presence of a moderate number of mitochondria and 
is suspected to have a combined phenotype of white and brown fat. The origin of 
marrow fat is the same as for WAT, which is from the marrow MSCs which can also 
differentiate into osteoblasts. Besides that, it plays an extensive role in regulating the 
lipid metabolism by clearing and storing circulating triglycerides, which can provide 
a localized energy reservoir for emergency situations like osteogenesis or bone 
fracture healing [150]. 
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Figure 2.4: Overview of adipocyte differentiation. MSCs differentiated from 
pluripotent stem cell precursors can further differentiate into myoblasts, 
chondroblasts, osteoblasts, and preadipocytes. Given the appropriate 
environmental and gene expression cues, preadipocytes undergo clonal expansion 
and turn into a mature adipocytes (taken from[151]). 
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2.3.2 Functions of adipocytes 
Adipose tissue produces different types of molecules such as cytokines, hormones, 
complement factors, prostacyclin, growth factors and enzymes. These molecules 
exhibit a numerous range of physiological functions including taking part in 
regulating the immune system (Tumor necrosis factor alpha (TNF-α), IL-1: IL-6, 
IL8, IL10), formation and maintenance of the vascular structure (vascular epithelial 
growth factor (VEGF), hepatocyte growth factor (HGF), angiotensin, plasminogen 
activator inhibitor-1 (PAI-1)), insulin sensitivity (resistin) and body weight (leptin 
and adiponectin) [152] . 
 
2.3.3 Role of adipocytes in obesity 
The development of obesity not only changes the morphology of adipocytes, but also 
alters their secretion profiles as shown in Figure 2.5. Adipocytes during the 
development of obesity are hypertrophic and most of the molecules that are produced 
by adipocytes are changed in terms of quantity or amount. Adipocytes secrete high 
amounts of fatty acids as well as adipokines, which promote insulin resistance and 
the ectopic accumulation of lipids in pancreas, liver and skeletal muscle. Moreover, 
obese adipose tissues may change the non-adipose tissues to adipose tissue-released 
by infiltrating to other organs. Lipid deposition in non-adipose tissue further 
contributes to metabolic stress, leading to loss of glucose homeostasis and resulting 
in tissue damage. For example, during the development of fatty liver, increased 
expression of proinflammatory cytokines and activation of Kupffer cells represents 
potential causes and sources of liver damage. During obesity, macrophages infiltrate 
into pancreatic islets and are likely to contribute to the local production of 
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proinflammatory cytokines. It has been reported that obesity is associated with 
endoplasmic reticulum stress in neurons leading to central leptin and insulin 
resistance, thereby further promoting obesity and loss of glucose homeostasis [46] . 
  




Figure 2.5: The roles of adipocytes during the development of obesity. Obesity 
induces the secretion of apelin, intracellular lipids, TNF-α, IL-6 and resistin in 
adipocytes, while suppressing the level of adiponectin. Besides that, obesity also 
contributes to hormonal changes such as an increase in the levels of oestrogen and a 
decrease in the level of testosterone (taken from [153]). 
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2.3.4 Influence of obesity and adipocytes on prostate cancer progression 
There is evidence to suggest that obesity is associated with prostate cancer 
development [18-20] and disease progression [21-23]. In a number of large cohort 
studies [18, 19] a higher body mass index was consistently found to increase the risk 
of prostate cancer. Obesity has been found to correlate with prostate cancer relapse 
after prostatectomy [22] or radiation therapy [23]. Besides that, adipocytes have long 
been suggested as a key component of the tumor microenvironment. Adipocytes 
isolated from periprostatic adipose tissues were found to induce invasiveness of 
prostate cancer cells [28] and it has been shown that prostate tumors frequently 
metastasizes to bone marrow, where half of the microenvironment is composed of 
adipocytes. Interestingly, adipocyte lineage cells were recently found to contribute to 
a functional skin stem cell niche, which stimulates follicular stem cell expansion 
[154]. Adipocytes adjacent to cancer cell were found to secrete cytokines (known as 
adipokines) such as IL-6 or IL-8 [155, 156], which have been shown to promote CSC 
self-renewal [157, 158]. These findings support the idea that cancer cells may 
architect their own stem cell niches through manipulation of the adipocyte, and that 
targeting of this adipocyte CSC niche provides therapeutic opportunities for the 
treatment of prostate cancer.  
 
2.3.5 Influence of leptin and adiponectin on prostate cancer progression. 
2.3.5.1 Leptin 
Leptin synthesis is mostly occurs in white adipose tissues, however, it still can be 
found in other tissues including the placenta, skeletic muscle, gastric epithelium, 
mammary gland. It not only plays an important role in regulating energy 
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homeostasis, but also has biological effects in several cellular processes such as 
reproduction, hematopoiesis, angiogenesis, and immunity. Leptin concentration is 
positively associated with the level of total body fat. Meanwhile, the induction of 
leptin concentration have been shown to correlate with testosterone and PSA levels 
in subjects with prostate cancer compared with subjects with benign prostate 
hyperplasia and the control group. Chang et al, [40] reported that the high leptin 
concentrations are positively associated with tumor volume. Furthermore, adipokine 
also increases the production of other cytokines and growth factors such as VEGF, 
which is involved in tumor progression [152]. 
 
2.3.5.2 Adiponectin 
Adiponectin is also produced by WAT and is the most abundant circulating 
adipokine which accounts for 0.05% of the total plasma proteins. Unlike other 
adipokines, the circulating levels of adiponectin are inversely proportional to obesity. 
Patients with breast, endometrium, colon and prostate cancer were found to have 
lower concentrations of adiponectin when compared to normal individuals. 
Adiponectin receptors have been found in prostate cancer cell lines (LNCaP-FGC, 
DU145 and PC-3). As reported by Miyasaky et al, [159], JNK and signal transducer 
and activator of transcription 3 (STAT3) were both involved in adiponectin-induced 
intracellular signalling. Besides that, it also found to play major roles in obesity, 
insulin resistance and as well in the tumor development. As a result, low adiponectin 
concentration can lead to the induction of cancer cells proliferation [152]. 
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2.3.6 Influence of aromatase and estrogens on prostate cancer progression. 
Aromatase is a P450 mono-oxygenase enzyme produced by adipocytes and increases 
during the development of obesity. In this situation, estrogens will also increase, 
however, androgens will decrease. This is because, in males, estrogens are derived 
from circulating androgens (testosterone) which is catalyzed by the aromatase 
enzymes. Estrogen signalling via ERα has been shown to induce inflammation and 
promote prostate cancer development. Furthermore, aberrant aromatase expression in 
prostate cancer has been suggested to contribute to the induction of inflammation and 
probably the development of an altered local hormonal milieu within prostate 
tumors. Besides that, based on previous studies, elevated levels of estrogen also 
enhance the growth of cancer cells [29]. 
 
2.3.7 Influence of adipocyte-secreted growth factors on prostate cancer 
progression. 
2.3.7.1 Transforming growth factor beta (TGFβ) 
TGFβ is the growth factor that is synthesized in the WAT [160] and can be mediated 
by heterodimeric type I and type II serine/threonine kinase receptors (TGFβ-RI or 
TGFβ RII). Some clinical studies have shown that TGFβ overexpression and loss of 
expression of TGFβ-RI or TGFβ RII are associated with greater pathological 
progression to metastasis. It has been suggested that in the absence of inhibitory 
autocrine TGFβ signalling, the high levels of secreted TGFβ promote prostate tumor 
growth and metastasis by acting as a paracrine factor on the tumor microenvironment 
[161]. Meanwhile, TGFβ is also known to regulate adipocyte function as well as 
obesity. As expected, TGFβ mRNA level was drastically higher in adipose tissue of 
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both ob/ob and db/db transgenic mice when compared with their lean counterparts. 
TGFβ expression has also been found to be increase during maturation of adipocytes 
[162]. These data suggest that obesity is associated with a higher expression of TGFβ 
in adipose tissues. Although, there is no strong evidence to prove the role of TGFβ in 
prostate cancer bone metastasis; however, previous study suggested that it may 




TNF-α is another example of a growth factor that is synthesised in WAT.  Similarly, 
it also increases during the obesity development and surprisingly, it was found to 
promote TGFβ synthesis [160]. As reported by previous studies, they suggested that 
the role of TNF-α in regulating the formation of bone metastasis. It was found to 
enhance DKK1 secretion (known to promote programmed cell death (PCD), which 
inhibits MSC derived osteoblastogenesis and lowers osteoprotegerin (OPG) levels 
and thus, results in reduced bone accretion. Furthermore, DKK1 secretion also 
enhances receptor activator of nuclear factor kappa-B ligand (RANKL) levels and 
thus increases the RANKL:OPG ratio and activates the osteoclast activity , leading to 
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Chapter 3: Research Paper 1: Tie-2 
regulates the stemness and 
metastatic properties of prostate 
cancer cells 
Within the bone marrow, there are two major cellular components: osteoblasts and 
adipocytes, which have been suggested to regulate the development and progression 
of prostate cancer, however, the underlying mechanisms remain largely unknown. As 
noted in the published review in Chapter 2, receptor tyrosine kinases are considered 
key therapeutic targets for prostate cancer. In this chapter, I have reported the 
discovery of a rare population of prostate cancer cells that express the Tie-2 protein, 
a receptor tyrosine kinase activated by the osteoblast-secreted cytokine Ang-1. 
Moreover, I have identified a novel Ang-1/Tie-2 autocrine loop in prostate cancer 
cells that promotes CSC quiescence and stemness. More importantly, I have 
demonstrated that Tie-2 positive prostate cancer cells are more metastatic compared 
to Tie-2 negative population. Based on these findings, I believe that my work has 
broadened the knowledge on how obsteoblasts contribute to a CSC niche in the bone 
marrow and regulate the stemness of prostate CSCs. Therefore, inactivation of the 
receptor tyrosine kinase, Tie-2 with currently available inhibitors may have the 
potential of developing into effective therapy for the advanced stage prostate cancer 
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3.1 Abstract 
Ample evidence supports that prostate tumor metastasis originates from a rare 
population of cancer cells, known as cancer stem cells (CSCs). Unfortunately, little is 
known about the identity of these cells, making it difficult to target the metastatic 
prostate tumor. Here, for the first time, we report the identification of a rare 
population of prostate cancer cells that express the Tie-2 protein. We found that this 
Tie-2
High 
population exists mainly in prostate cancer cell lines that are capable of 
metastasizing to the bone. These cells not only express a higher level of CSC 
markers but also demonstrate enhanced resistance to the chemotherapeutic drug 
Cabazitaxel. In addition, knockdown of the expression of the Tie-2 ligand 
angiopoietin (Ang-1) led to suppression of CSC markers, suggesting that the Ang-
1/Tie-2 signaling pathway functions as an autocrine loop for the maintenance of 
prostate CSCs. More importantly, we found that Tie-2
High 
prostate cancer cells are 
more adhesive than the Tie-2
Low
 population to both osteoblasts and endothelial cells. 
Moreover, only the Tie-2
High
, but not the Tie-2
Low
 cells developed tumor metastasis 
in vivo when injected at a low number. Taken together, our data suggest that Tie-2 
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3.2 Introduction 
Prostate cancer is one of the most common solid tumors in men and is the second 
leading cause of morbidity and mortality in men worldwide [31, 165]. Patients with 
advanced prostate cancer are normally treated with hormone ablation therapy. This 
therapy is effective initially, as prostate cancer cells require androgen to grow and 
survive; however, the cancer cells eventually become androgen-independent and 
develop metastatic, castration-resistant tumors [2]. At this stage, chemotherapy and 
radiotherapy have only minor benefits. As a result, advanced prostate cancer remains 
incurable with current treatment strategies [4]. 
 
Recent studies suggested that prostate tumor-initiating cells (TICs)/cancer stem cells 
(CSCs) may play key roles in the initiation, progression and treatment failure of the 
disease [166-168]; however, their exact identity remains unclear. These cells share 
many similarities with normal stem cells, including the ability to differentiate into 
cells of different lineages and the dependence on a stem cell niche for the 
maintenance of their stemness. Interestingly, according to previous studies, CSCs are 
capable of creating their own CSC niche by recruiting mesenchymal stem cells 
derived from bone marrow [16]. CSCs can also ‘hijack’ the established normal stem 
cell niches [5]; as has been demonstrated in both human and mouse models of 
prostate and breast cancers. According to Shiozawa et al. [17], prostate CSCs are 
capable of competing with hematopoietic stem cells (HSCs) for the bone marrow 
niche. Moreover, prostate cancer cells that occupy the niche were found to express 
the CXCR4 receptor, which is responsible for mediating the interaction between 
HSCs and the niche. By blocking the CXCL12/CXCR4 pathway, prostate cancer 
bone metastasis was significantly suppressed, supporting the hypothesis that prostate 
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tumors metastasize to the bone by adopting this bone-homing signaling pathway. 
However, although disseminated prostate cancer cells can be detected in the bone 
marrow of prostate cancer patients, bone metastasis may take years to develop. This 
may reflect the time required for the disseminated cancer cells to establish a suitable 
tumor microenvironment before the cells can grow exponentially. Therefore, a better 
understanding of the bone marrow stem cell niche and its role in supporting bone 
metastasis may aid the development of effective treatments. 
 
Tie-2 is a membrane receptor commonly expressed by HSCs, osteoblasts and 
endothelial cells. It binds to and is activated by angiopoietin-1 (Ang-1), a cytokine 
actively secreted by osteoblasts within the bone marrow niche [169-171]. Similar to 
the KITLG/c-Kit, CXCL12/CXCR4 and FGF1/FGFR chemokine axes, the Ang-
1/Tie-2 signalling pathway also plays a key role in regulating the homing and 
stemness of HSCs [30, 172-175]. According to Arai et al. [30], Tie-2 receptors are 
expressed by the quiescent HSCs that adhere to osteoblasts within the inner surface 
of the bone. The same group further demonstrated that osteoblasts secrete a large 
amount of Ang-1, which promotes the adhesion of HSCs to osteoblasts while 
maintaining the cells in a quiescent state. Recently, the Ang-1/Tie-2 signalling 
pathway was also found to promote muscle satellite cell self-renewal [176]. Apart 
from regulating normal stem cells, Tie-2 was also found to play a role in cancer 
progression. As reported by Lee et al. [177], Tie-2 was found to be expressed by 
neoplastic glial cells, and its expression level was significantly associated with 
disease progression. Tie-2 activation was also found to correlate with 
chemoresistance [178]. Further research by the same group demonstrated that Tie-2 
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promoted glioma cell invasion and modulated the interaction of glioma tumor stem 
cells with endothelial cells [179]. 
 
In this study, we show that Tie-2 is expressed by a rare population of prostate cancer 





prostate cancer cells demonstrate not only enhanced chemoresistance but 
also an increased ability to adhere to stromal cells such as endothelial cells and 
osteoblasts. Intra-cardiac injection of the cells into immune-incompetent mice 
confirmed that Tie-2
High 
cells, but not Tie-2
Low
 cells, actively developed into 
metastatic tumors in vivo. Our data, therefore, have demonstrated a novel role for 
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3.3 Results 
3.3.1 Identification of a rare population of Tie-2High prostate cancer cells 
Although Ang-1/Tie-2 is one of the key signalling pathways involved in HSC 
maintenance, it is currently unknown whether it plays any role in prostate cancer 
progression. To address this question, we first examined whether prostate cancer 
cells express Tie-2. Using a PE-conjugated anti Tie-2 antibody, the expression level 
of the Tie-2 receptor in a panel of prostate cancer cell lines with different metastatic 
potential (LAPC4, 22Rv1, DU145, LNCaP, C42B, MDA-PCa-2b and PC-3) was 
determined by flow cytometry. As shown in Figure 3.1A and 3.1B, Tie-2 positive 
cells exist at a very low level in soft tissue metastatic prostate cancer cell lines 
(between 0.1 - 0.15%). However, the Tie-2 positive population was found higher in 
C42B (a bone metastatic cell line derived from LNCaP) (0.35%), and two bone 
metastatic prostate cancer cell lines (0.33% and 0.39% in PC-3 and MDA-PCa-2b 
respectively). Consistently, qRT-PCR analysis revealed that Tie-2 mRNA was 
expressed at a higher level in the bone metastatic prostate cancer cell lines (Figure 
3.1C). More importantly, Tie-2 was also found to be expressed not only in PC-3 
tumors metastasized into a humanized bone scaffold (left panel) established in our 
previous study [180], but also in bone metastatic tumor of human prostate cancer 
patient (right panel), further suggesting that Tie-2 may play roles in the development 
of prostate tumor bone metastasis (Figure 3.1D).  
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Figure 3.1: Expression of Tie-2 in prostate cancer cells. (A&B) Flow cytometry 
analysis of Tie-2 expression in a panel of prostate cancer cell lines (LAPC4, 22Rv1, 
DU145, LNCaP, C42B, MDA-PCa-2b and PC-3). The results are presented as the 
mean ± SD from triplicate experiments. (C) Tie-2 mRNA was analyzed in these 
different prostate cancer cell lines using qRT-PCR. Note that Tie-2 protein and 
mRNA expression were both increased in bone metastatic prostate cancer cell lines 
(highlighted). Results quantified represented as fold change normalized to DU145. 
(D) Immunohistochemical staining was performed on humanized bone scaffold 
containing the PC-3 metastastic tumor (5 cases) (left panel) and human bone section 
containing the metastatic prostate tumor (1 case) (right panel). All the sections were 
stained with antibody against Tie-2. Note that, all the sections were positive for the 
Tie-2 proteins and the arrows showed the positive staining within the tumor cells 
(40X magnifications). (p values: *** < 0.005). 
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3.3.2 Co-expression of stem cell markers with Tie-2 in prostate cancer cells 
To further characterize the Tie-2 positive prostate cancer cells, we first performed 
FACS to enrich the Tie-2-positive population from PC-3 cells. Analysis of the 
population sorted by flow cytometry confirmed the successful enrichment of Tie-
2
High 
cells (Figure 3.2A) by cell sorting. cDNA microarray analysis was then 
performed to examine the gene expression profile of Tie-2
High 
cells. As shown in in 
Suppl.  Table A.2, several stem cell factors/markers commonly found in HSCs (e.g. 
FGF1, KITLG and CXCR4) were found to be upregulated in the Tie-2
High 
population, 
which was further confirmed by qRT-PCR analysis (Figure 3.2B), demonstrating that 
Tie-2 expression is associated with upregulation of HSC markers. 
3.3.3 Tie-2 regulates the quiescence of prostate cancer cells 
One of the key roles of Tie-2 is to regulate the quiescence state of HSCs. To 
determine if expression of Tie-2 is associated with cellular quiescent, HO/PY 





 prostate cancer cells. As expected, the population of quiescent cells was 
increased more than 3-fold in the Tie-2
High 
population when compared to the Tie-2
Low 
population (Figure 3.2C), suggesting that Tie-2 expression plays an important role in 
maintaining the quiescent state of prostate cancer cells. Cellular quiescence has been 
shown to contribute to the chemodrug resistance of CSCs. We therefore examined 
the sensitivity Tie-2
High 
prostate cancer cells to Cabazitaxel, a chemotherapeutic drug 
commonly used for the treatment of prostate cancer. As shown in Figure 3.2D, 
treatment of the Tie-2
Low 
population with Cabazitaxel led to induction of apoptosis of 
48% cells, as evidenced by Annexin V staining. However, the apoptotic population 
 Dissecting the prostate cancer  stem cell niche inside the bone marrow. 77
was significantly lower in Tie-2
High
 cells under the same conditions (<35%), clearly 
demonstrating that Tie-2 expression is associated with Cabazitaxel resistance. 
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Figure 3.2: The Tie-2
High
 population possessed stem cell characteristics. (A) 
Analysis of the population sorted by flow cytometry confirmed the successful 
enrichment of Tie-2
High
 cells. (B) Validation of the selected candidate genes (i.e., 
KITLG, CXCR4, and FGF1) with qRT-PCR. Results were normalized with internal 
control and are presented as fold change relative to Tie-2
Low 
population. (C) Flow 
cytometry analysis revealed that quiescent cells were increased by more than 3-fold 
in the Tie-2
High
 population when compared to the Tie-2
Low
population. (D) Flow 





cells that were treated with 100nM Cabazitaxel for 72hrs (p value = 0.0018 for 
apoptosis). Note that a high percentage of apoptotic cells were detected in the Tie-
2
Low
 population when compared to the Tie-2
High
 prostate cancer cells. (p values: * < 
0.05, ** < 0.005, *** < 0.0005).  
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3.3.4 Ang-1 activates the Tie-2 downstream signalling pathway in prostate 
cancer cells 
Because the Ang-1/Tie-2 signalling cascade plays a role in the regulation of HSC 
stemness, we therefore questioned whether Ang-1 also regulates the stemness of 
prostate cancer cells. We first treated PC-3 cells with increasing doses of 
recombinant Ang-1 (0, 200 and 600 ng/ml) for 72 hours under serum-free conditions. 
The expression of a series of stem cell factors/markers known to be induced by the 
Ang-1/Tie-2 signalling in HSCs was then examined by Western blotting. As shown 
in Figure 3.3A (left panel), Ang-1 induced a dose-dependent increase in AKT 
phosphorylation, a direct downstream target of the Ang-1/Tie-2 signalling pathway, 
confirming that Tie-2 activates prostate cancer cells. More importantly, Ang-1 
treatment was found to induce the expression of prostate CSC (CD49f and Bmi-1) 
and quiescence (p27) markers in PC-3 cells in a dose-dependent manner. When the 
cells were treated with a Tie-2 kinase inhibitor (0, 1 and 5 µM), a cell permeabile 
pyridinylimidazole found to block the kinase activity of Tie-2 [181], all the markers 
tested were found to be downregulated, suggesting that activation of Tie-2 is required 
for maintaining the levels of these markers (Figure 3.3A, right panel). To confirm 
our findings, cells were transfected with two different siRNAs that target different 
regions of the Tie-2 mRNA, which resulted in a significant decrease (>50%) in the 
Tie-2 mRNA level (Figure 3.3B). As shown in Figure 3.3C, knockdown of Tie-2 led 
to concomitant decrease in the level of CD49f, Bmi-1 as well as p27. More 
interestingly, the effect of recombinant Ang-1 was significantly suppressed when the 
cells were pre-treated with the Tie-2 inhibitor (Figure 3.3D, left panel) or Tie-2 Fc 
Chimera (Tie-2 neutralizing peptide) (Figure 3.3D, right panel). Furthermore, ectopic 
expression of Tie-2 in DU145 cells, which lack endogenous Tie-2 expression (Suppl.  
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Figure A.1A) and fail to respond to Ang-1 (data not shown), was found to 
successfully restore the response of the cells to Ang-1 treatment (Suppl. Figure 
A.1B), further supporting the hypothesis that activation of Tie-2 by Ang-1 is crucial 
for maintaining the expression of stem cell markers in prostate cancer cells. 
Since Ang-1 regulates the stemness of HSCs through induction of cellular 
quiescence, we therefore examined if Ang-1 treatment also induces quiescent of the 
prostate cancer cells. PC-3 cells were first treated with Ang-1 before being stained 
with HO/PY for quantitation of quiescent population. As shown in Figure 3.3E&F, 
when cells were treated with recombinant Ang-1, a 4-fold increase in the quiescent 
population was observed. Consistently, expression of p27, a protein closely 
associated with cell cycle arrest and cellular quiescence, was also found to be 
induced by Ang-1 treatment in PC-3 cells (Figure 3.3A). Meanwhile, inactivation of 
Tie-2 using siRNA (Figure 3.3C), a Tie-2-specific inhibitor or a Tie-2 Fc chimera 
(Figure 3.3D) also led to suppression of p27, even in the presence of recombinant 
Ang-1, further suggesting that Ang-1 induces quiescence of prostate cancer cells 










 Dissecting the prostate cancer  stem cell niche inside the bone marrow. 83
 
Figure 3.3: Ang-1 upregulated prostate CSC and quiescent markers in prostate 
cancer cell lines. Western blotting (A) of prostate CSC markers (CD49f and Bmi-1) 
and a quiescence marker (p27) after Ang-1 treatment in PC-3 cells (left panel). Ang-
1 was found to upregulate both stem cell and quiescence markers in a dose-
dependent manner. The Tie-2 inhibitor, on the other hand, suppressed both types of 
markers in a dose-dependent manner in PC-3 cells (right panel). (B) Transfection of 
Tie-2 siRNAs led to downregulation Tie-2 mRNA levels in PC-3 cells. Results were 
normalized with internal control and are presented as fold change relative to 
scramble. (C) Effect of Tie-2 knockdown on CSC and quiescence marker expression 
in PC-3 cells. (D) The experiment was repeated in the presence of Tie-2 inhibitor 
(left panel) or a Tie-2 neutralizing antibody (right panel), which showed that both the 
Tie-2 inhibitor and Tie-2 neutralizing antibody abolished the effect of Ang-1 on PC-
3 cells. (E) Quantitation of the quiescent population in PC-3 cells with or without 
Ang-1 treatment. Note that Ang-1 treatment led to a 4-fold induction of the quiescent 
population in PC-3 cells when compared to the vehicle control. Each experiment was 
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repeated at least three times, and the results are presented as the mean ± SD. (p 
values: * < 0.05, ** < 0.005, *** < 0.0005). 
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3.3.5 Ang-1 functions as a novel autocrine factor in prostate cancer cells 
Because prostate cancer cells are known to secrete Ang-1, we hypothesized that Ang-
1 may indeed function as an autocrine factor in prostate cancer cells. To test this 
hypothesis, we first confirmed the expression of Ang-1 mRNA in the prostate cancer 
cell lines with qRT-PCR. Consistent with previous studies, Ang-1 mRNA was 
detectable in prostate cancer cell lines, and its expression is found higher in bone 
metastatic prostate cancer cell lines, C42B and PC-3 (Figure 3.4A). Nevertheless, 
transfection of PC-3 cells with two different Ang-1 siRNAs led to >80% suppression 
of the Ang-1 mRNA level, as shown in Figure 3.4B. More importantly, knockdown 
of endogenous Ang-1 resulted in suppression of both CSC (CD49f an Bmi-1)  and 
quiescence (p27) markers in PC-3, supporting the hypothesis that Ang-1 produced by 
cancer cells is crucial for CSC maintenance (Figure 3.4C). Surprisingly, examination 
of Ang-1 secretion with ELISA revealed that C42B produced the highest level of 
Ang-1 among all the prostate cancer cell lines (Figure 3.4D). Meanwhile, we found 
that C42B cells failed to respond to treatment with Ang-1 recombinant proteins (data 
not shown); however, knockdown of endogenous Ang-1 not only suppressed the 
expression of  CD49f an Bmi-1, but also restored the response of the cells to 
exogenous Ang-1 treatment, as evidenced by the induction of CSC and quiescence 
markers by recombinant Ang-1 (Figure 3.4E-G). These findings further confirm that 
Ang-1 regulates the stemness of prostate cancer cells by functioning as an autocrine 
factor. 
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Figure 3.4: Ang-1 functioned as an autocrine factor in prostate cancer cells. (A) 
Ang-1 mRNA expression was determined in different prostate cancer cell lines 
(DU145, C42B and PC-3) using qRT-PCR analysis. Results were normalized with 
internal control and are presented as fold change relative to DU145. (B) Knockdown 
of Ang-1 in PC-3 cells by siRNA transfection was confirmed with qRT-PCR and 
ELISA. Note that Ang-1 expression was suppressed by >80% in PC-3 cells. Results 
were normalized with internal control and are presented as fold change relative to 
scramble. (C) Downregulation of Ang-1 in PC-3 cells by siRNA was associated with 
suppression of CSC (CD49f and Bmi-1) and quiescence (p27) markers. (D) Ang-1 
secretion (pg/ml) by different prostate cancer cell lines (DU145, C42B and PC-3) 
was determined with an ELISA. (E) Knockdown of Ang-1 for >50% was confirmed 
with RT-PCR in C42B cells. (F) Ang-1 knockdown suppressed both CSC (CD49f 
and Bmi-1) and quiescence (p27) markers in C42B cells. (G) The response of C42B 
cells to exogenous Ang-1 treatment (600ng/ml) was restored when endogenous Ang-
1 was knocked down by siRNA. (p values: * < 0.05, ** < 0.005, *** < 0.0005). 
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3.3.6 Tie-2 facilitates the adhesion of prostate cancer cells to osteoblasts and 
endothelial cells 
One of the functions of Tie-2 in HSC maintenance is to facilitate the adhesion of 
HSCs to osteoblasts, which is a process that is also required by prostate cancer cells 
during the development of bone metastasis. This led us to speculate that Tie-2 may 
also regulate the adhesion of prostate cancer cells to osteoblasts. The ability of the 
Tie-2
High 
population to adhere to osteoblasts was then determined with a cell 
adhesion assay using the osteosarcoma cell line (MG-63). Examination of the cells 
that adhered to a confluent monolayer of MG-63 cells revealed a significant increase 
in the adhesion ability of the Tie-2
High 
population to osteoblasts when compared to 
the Tie-2
Low
 cells (Figure 3.5A). This adhesion ability was completely abolished in 
the presence of the Tie-2 inhibitor, although the same treatment failed to affect the 
adhesion ability of the Tie-2
Low
population (Figure 3.5B). A similar result was 
observed in another osteosarcoma cell line (SaOS-2) (Suppl. Figure A.2A & B). 
Strikingly, we found that the Tie-2
High 
population also showed an increased ability to 
adhere to endothelial cells (Figure 3.5D), which again could be abolished by the 
addition of the Tie-2 inhibitor (Figure 3.5E). To determine whether this effect of Tie-
2 is specific to PC-3 cells, we repeated the cell adhesion assay with DU-Tie-2-GFP. 
Similar to Tie-2
High 
PC-3 cells, DU-Tie-2-GFP cells also demonstrated increased 
adhesion to both MG-63 and HUVECs when compared to the control cells (DU-
GFP), as shown in Figure 3.5C&F. Meanwhile, the adhesion ability of DU-Tie-2-
GFP cells to MG-63 and HUVECs was also able to abolish by the addition of Tie-2 
inhibitor as shown in Suppl. Figure A.2C & D. Recently, Ang-1 has been shown to 
promote the bridging of intercellular Tie-2 [182]. Considering that osteoblasts 
express high levels of Tie-2, it is possible that the cell adhesive ability of the Tie-2 
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positive prostate cancer cells is mediated through bridging of the intercellular Tie-2. 
Nevertheless, these findings provide strong evidence that Tie-2 promotes the 
adhesion of prostate cancer cells to both endothelial cells and osteoblasts. 
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Figure 3.5: Tie-2 facilitated the adhesion of prostate cancer cells to osteoblasts 




PC-3 cells prestained with Hoechst 33342. Cells that adhered to 
osteoblasts (MG-63) (A) or endothelial cells (HUVECs) (D) were quantified by 
measuring the fluorescence intensity, and the results are presented as the mean ± SD. 
Note that Tie-2
High 
PC-3 cells were more adhesive to MG-63 and HUVECs when 
compared to Tie-2
Low
PC-3 cells. (B&E) Effect of Tie-2 inactivation on the adhesive 
ability of Tie-2
High
 PC-3 cells. Treatment with a Tie-2 inhibitor (5 µM) prior to the 
adhesion assay significantly suppressed the adhesion ability of Tie-2
High 
cells, while 
the same treatment failed to affect the Tie-2
Low 
population. (C&F) Ectopic Tie-2 
expression promoted the adhesion of DU145 cells to osteoblast MG-63 cells and 
HUVECs. Each experiment was repeated at least three times, and the results are 
presented as the mean ± SD. (p values: * < 0.05, ** < 0.005, *** < 0.0005). 
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3.3.7 Tie-2 enriched cells are highly metastatic in vivo 
Because we found that higher levels of Tie-2 were expressed in metastatic prostate 
cancer cell lines, and conferred the preferential ability to induce a stem cell-like 
phenotype and cell adhesion ability of the cancer cells, we hypothesized that Tie-2 
may play an important role in prostate tumor metastasis. To test this hypothesis, we 
examined the ability of Tie-2
High 
prostate cancer cells to form metastatic tumors in 




cells isolated from the PC-3-Luc cell line 
were injected into the mice via intra-cardiac injection as shown in Figure 3.6A. 
Subsequent development of metastatic tumors was then determined by 
bioluminescence (Figure 3.6B) and ex vivo (Figure 3.6C and Suppl. Figure A.3) 
imaging. While mice injected with the Tie-2
Low
 cells failed to develop any tumors, 
metastatic tumors were found in 3 out of the 8 mice that were injected with the Tie-
2
High
 population. Of the 3 mice that developed tumors, two exhibited bone metastasis 
and one exhibited soft tissue metastasis to the kidney, as shown in Figure 3.6D. 
These data strongly support that Tie-2
High 
prostate cancer cells are highly metastatic 
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Figure 3.6: The Tie-2
High





populations sorted out by FACS were injected into mice via intracardiac 
injection (top). An experimental regimen showing the intracardiac implantation and 
monitoring of tumor metastasis is shown below. (B) Representative bioluminescence 
images of a mouse from each group 4 and 8 weeks after the implantation. (C) Ex vivo 
imaging of the Tie-2
High
 metastatic tumor in rib cage (Left) and kidney (Right). (D) 
Summary of the metastatic tumors detected in each mouse. Three out of the eight 
mice that were injected with Tie-2
High
 cells exhibited metastasis (two in the bone and 
one in the kidney) (p < 0.05). (See also Suppl. Figure A.3) 
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3.4 Dissussion 
In this study, we showed that a rare population of Tie-2-positive cells are present in 
bone metastatic prostate cancer cell lines (PC-3, C42b and MDA-PCa-2b). These 
cells not only demonstrated an increased ability to adhere to osteoblasts and 
endothelial cells but were also found to be more resistant to chemotherapeutic drugs 
when compared to the Tie-2
Low 
population. More importantly, we found that these 
cells were capable of developing into metastatic tumors in vivo, even when a low 
number of cells were injected. These cells may thus represent the prostate CSC-like 
population, which contributes to treatment failure and disease metastasis.  
 
Ample evidence has suggested that CSCs isolated from solid tumors share similar 
characteristics with HSCs [43, 183, 184]. Indeed, several signalling pathways 
involved in HSC maintenance were also found to be activated in CSCs. For example, 
CXCL12/CXCR4 was found to be a key regulator of tumor dissemination in cancer 
cells [185-187], including prostate cancer cells [17, 142] and it also plays an 
important role in the activation of prostate progenitor cells [188]. Recently, 
KITLG/c-Kit was found to be involved in CSC maintenance in different cancer 
types, including prostate cancer [35, 189-191]. Moreover, these studies also showed 
that the c-Kit receptor was highly expressed in human prostate tumors that 
metastasized to the bone [29]. It is therefore not surprising that the Ang-1/Tie-2 
signaling pathway may also play a key role in regulating the stemness of prostate 
CSCs, particularly because Tie-2 was found to be expressed by glioma stem cell 
populations [179]. Indeed, our results suggest that activation of Tie-2 may be 
required for maintaining both the stemness and quiescent state of prostate cancer 
cells. The finding that the Tie-2
High 
population was more resistant to Cabazitaxel 
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further supports this notion. Meanwhile, we also observed a significant increase in 
HSC factors/markers (KITLG, CXCR4 and FGF1) in Tie-2
High
 PC-3 cells when 
compared to the Tie-2
Low 
population, further suggesting that Tie-2
High
 prostate cancer 
cells are similar to HSCs. 
 
Prostate cancer cells are known to actively secrete a large amount of Ang-1, which 
induces tumor angiogenesis by binding to and activating Tie-2 in endothelial cells 
[192, 193]. Our finding that prostate cancer cells also express functional Tie-2 
suggests that Ang-1 may also function through an autocrine loop. Indeed, 
knockdown of either Ang-1 or Tie-2 was found to downregulate CSC and quiescence 
markers in PC-3 and C42B cells. Further support was derived from the finding that 
C42B cells, which express the highest level of Ang-1, failed to respond to exogenous 
Ang-1 unless endogenous Ang-1 was knocked down by siRNA transfection (data not 
shown). It is worth noting that autocrine loops such as KITLG/c-Kit and 
CXCL12/CXCR4 may also exist, although their underlying functions and therapeutic 
potential remain to be elucidated.  
 
Apart from regulating the stemness of HSC, the Ang-1/Tie-2 pathway is also known 
to facilitate the adhesion of HSCs to the osteoblastic niche [30]. Similarly, in our in 




 PC-3 cells were more 
adhesive to osteosarcoma MG-63 and SaOS-2 cells. This result suggests that Tie-2 
receptor may also play a key role in mediating the adhesion of prostate cancer cells 
to osteoblasts. This possibility was further confirmed by our finding that Tie-2 
overexpression promoted the adhesion of DU145 cells to osteoblast cells. 
Interestingly, similar effects were also observed in endothelial cells, where Tie-2
High
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PC-3 cells showed increased adhesion to endothelial cells, where Tie-2
High
 PC-3 
showed increased adhesion to endothelial cells. Because both intravasation and 
extravasation of tumor cells required their active adhesion to endothelial cells [194, 
195], it is conceivable that Tie-2 may play roles in both processes during the 
development of prostate tumor metastasis and that Tie-2
High
 prostate cancer cells are 
likely to be more metastatic. This was indeed confirmed by the finding that injection 
of only 3,000 Tie-2
High 
cells could induce the formation of metastatic tumors in vivo. 
Interestingly, kidney metastasis was found in one of the mice, which may reflect the 
rich blood supply of the kidney tissue. Indeed, sub-renal capsule grafting has been 
shown to provide the optimum microenvironment for tumor growth, and was most 
efficient in terms of uptake rate (>90%) for both benign and malignant prostate 
tissues [196]. 
 
In summary, we have demonstrated for the first time that Tie-2 is expressed by a rare 
population of prostate cancer cells and plays an important role in regulating the 
stemness and metastatic ability of the cells (summarized in Suppl. Figure A.4). Our 
results highlight the therapeutic potential of targeting Tie-2 with existing inhibitors 
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3.5 Materials and Methods 
qRT-PCR analysis 
 
Total RNA was isolated using an RNeasy Mini Kit (Qiagen, Germantown, MD, 
USA) following the manufacturer’s instructions. Two micrograms of RNA were used 
to synthesize cDNA using the SuperScript® III First-Strand Synthesis Systems 
(Invitrogen, Carlsbad, CA, USA). qRT-PCR was carried out with the ViiA™ 7 Real-
Time PCR System (Applied Biosystems, Foster City, CA, USA). Sense and anti-
sense primers targeted against the genes of interest are listed in Suppl. Table A.1. 
The transcript level of ribosomal protein L32 (RPL32) was used as an internal 
control. 
 
Small interfering RNA 
Small interfering RNAs (siRNAs) targeting Tie-2 (J-003178-11 and J-003178-12) 
and Ang-1  (J-007802-07  and J-007802-08) as well as a scrambled RNA oligo were 
purchased from Dharmacon, Lafayette, CO, USA. Cells were transfected with the 
indicated siRNA using Lipofectamine RNAiMax (Invitrogen) following the 
manufacturer’s instructions. Forty-eight hours after transfection, the cells were lysed 
for Western blotting analysis or for RNA extraction and qRT-PCR analysis. 
 
Flow cytometry analysis and fluorescence-activated cell sorting (FACS) 
Cells were collected, washed twice with phosphate-buffered saline (PBS) and 
resuspended in 50 l of FACS buffer (0.02% sodium azide and 2% FBS in PBS) 
before incubating with the fluorescent dye-conjugated antibodies at 4°C in the dark 
for 30 minutes. After incubation, the cells were washed twice with PBS and 
subsequently resuspended in 200 l of FACS buffer. Flow cytometry analysis was 
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performed using BD™ LSR II as described in the manufacturer’s instruction manual, 
and the results were analyzed using KALUZA software. 
For cell sorting, PC-3 cells were stained with Phycoerythrin (PE)-conjugated Tie-2 
antibody in 200 l of FACS buffer (2% FBS in PBS) at 4°C in the dark for 2 hours 
and the corresponding IgG isotype was used as negative control. After incubation, 
cells were washed twice with PBS and then resuspended in 500 l of FACS buffer. 
The Tie-2
High 
population was sorted using the Beckman Coulter MoFloAstrios 
 
Immunohistochemistry (IHC) 
Sections rehydrated with standard procedures were incubated with 3% hydrogen 
peroxide (Sigma-Aldrich) for 10 minutes at room temperature. Antigen retrieval was 
performed with sodium citrate buffer at pH 6 in a pressure cooker for 10 minutes. 
Sections were then blocked with normal goat serum diluted in TBS for 1 hour.  After 
the blocking, the sections were incubated with antibody against Tie-2 (1: 5000) 
(Santa Cruz Biotechnology, Dallas, TX, USA) for 1 hour, followed by a 1 hour 
incubation with biotinylated rabbit secondary antibody (Vector Laboratories, 
Burlingame, CA, USA) and a 30 minute incubation with VECTASTAIN® ABC 
Reagent complex. Signals were developed with the ImmPACT DAB Peroxidase 
(HRP) Substrate (Vector Laboratories). Slides were then counterstained with 
hematoxylin (Biocare Medical, Concord, CA, USA) before being mounted for 
analysis under the microscope. 
 
Generation of the stable Tie-2 overexpressing line 
DU145 cells overexpressing Tie-2 (DU-Tie-2-GFP) were generated using the 
lentiviral gene delivery system as described in our previous study [198]. Briefly, 
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pLenti6-Tie-2-GFP or the empty vector control was transfected into 293FT cells for 
lentiviral packaging. Viruses were collected and used to infect DU145 cells in the 
presence of polybrene (8 g/ml). Positive transfectants were selected with blasticidin 
(10 g/ml) and were further enriched by FACS based on the GFP signal. 
 
Western blot 
Details regarding the experimental procedures have been described in our previous 
studies [197]. Briefly, whole cell lysates were prepared by lysing cell pellets with 
lysis buffer (Cell Signaling) containing 100 µM phenylmethylsulfonyl fluoride 
(PMSF; Sigma-Aldrich, St. Louis, MO, USA). The cell lysates were quantitated 
using the Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL, 
USA) before loading onto a SDS-polyacrylamide gel. The resolved proteins were 
then transferred onto a PVDF membrane (Millipore, Billerica, MA, USA), and the 
membrane was subsequently probed with the indicated antibody for 1 hour at room 
temperature prior to being washed with TBS-T buffer. The membrane was then 
incubated with the corresponding secondary antibodies for another hour at room 
temperature. After washing with TBS-T buffer, the membrane was incubated with 
Immobilon Western Chemiluminescent HRP Substrate (Millipore), and the signals 
were visualized using a Bio-Rad ChemiDoc™ XRS Gel Documentation System. 
 
Hoechst33342/ Pyronin Y (HO/PY) quiescent staining  
To determine the percentage of quiescent cells, all cells were first stained with 10 
g/ml HO for 45 minutes in the dark at 37°C. The cells were then incubated with 5 
M PY for another 45 minutes in the dark at 37°C as described in previous studies 
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[198-200]. After staining, the cells were analyzed using BD™ LSR II, and the results 
were further analyzed using KALUZA software. 
 
Annexin V staining 
To determine the percentage of apoptotic cells, Annexin V staining was performed 





 PC-3 cells were washed twice with cold 
PBS, resuspended in 100l of 1X binding buffer and then incubated with Annexin V-
FITC antibody and propidium iodide in the dark at room temperature for 15 minutes. 
After incubation, the apoptotic cells were analyzed using BD™ LSR II, and the 
results were further analyzed using KALUZA software. 
 
Ang-1 ELISA 
To quantitate Ang-1 secretion by the prostate cancer cells, the cells were cultured in 
serum-free medium for 24 hours. The cells were harvested and counted using a 
Scepter
™
 Automated Cell Counter (Millipore). Conditioned medium was collected 
and concentrated using the 10K Amicon Ultra2-ml Centrifugal Filters (Millipore). 
The medium was analyzed using the Human Angiopoietin-1 DuoSet kits (R&D 
Systems, Minneapolis, MN, USA) following the manufacturer’s instructions and the 
positive signals were determined using a LUMIstar OPTIMA Luminescence 
Microplate Reader and then, normalized it to the cell numbers. 
 
Cell adhesion assay 
Prostate cancer cell lines were first labelled with HO for 45 minutes. Labelled cells 
(3 X 10
3
) were then overlaid directly onto confluent HUVECs, MG-63 cells or 
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SaOS-2 cells. The cells were incubated for 30 minutes in the dark at 37°C. 
Unattached cells were dispersed with PBS, and the adherent cells were quantified 
using a LUMIstar OPTIMA Luminescence Microplate Reader. This experiment was 
repeated in the presence of 5 M Tie-2 inhibitor or an equal volume of DMSO as a 




All animal studies were conducted in accordance with the Australian Code of 
Practice for the Care and Use of Animals for Scientific Purposes and were approved 
by the Animal Ethics Committee at the Queensland University of Technology 
(Approval No: 1100001393). Tumor metastasis were examined via intra-cardiac 
tumor cell injection using procedures described previously [180]. Briefly, the Tie-
2
High 
population was isolated from PC3-Luc cells, which were stably transfected with 





were suspended in 100 l of PBS before injecting into the left cardiac ventricle of 6-
8-week-old male NOD-SCID mice (n = 8). Tumor metastasis were monitored every 
2 weeks for a total of 8 weeks by intraperitoneal injection of D-luciferin (150 mg/kg) 
followed by bioluminescence imaging. The signal was detected using the Xenogen 
IVIS 100 imaging system. Mice were sacrificed at the end of the experiment, and ex 
vivo bioluminescence imaging was performed to confirm the incidence of metastasis. 
Statistical analysis was performed with the two-tailed t test, and differences were 
considered to be significant if p < 0.05. 
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3.6 Supplementary Tables and Figures 
Suppl. Table A.1: List of the primers used in this study. 
Primer name Sequence 
Tie-2 forward 5′-CTTTCTGGAACTGTGGAAGG-3′ 
Tie-2 reverse 5′-CTGGTGCTGGTTCATTAAGG-3′ 
KITLG forward 5′-CTGCTCCTATTTAATCCTCTCGT-3′ 
KITLG reverse 5′-TTGTACTACCATCTCGCTTATCC-3′ 
CXCR4 forward 5′- GCAGCAGGTAGCAAAGTGAC -3′ 
CXCR4 reverse 5′-AGAAGATGATGGAGTAGATGGTGG-3′ 
FGF1 forward 5′-ACAAGAAGCCCAAACTCCTC-3′ 
FGF1 reverse 5′-GTTCTCCTCCAGCCTTTCCA-3′ 
ANGPT1 forward 5′-ACGATGGCAACTGTCGTGAG-3′ 
ANGPT1 reverse 5′-TCCGACTTCATGTTTTCCACAA-3′ 
 
Suppl. Table A.2: Summary of cDNA microarray analysis.  
 
The fold induction of stem cell factors and markers in Tie-2
High
 population when 
compared to Tie-2
Low
 population as determined by cDNA microarray analysis. Each 
experiment was repeated at least twice.  
Gene 
Symbol Description RefseqID 
Fold 
Change 
FGF1 fibroblast growth factor 1 (acidic) (FGF1), transcript variant 6, mRNA. NM_001144935 4.9 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A), transcript variant 
2, mRNA. NM_078467 2.8 
PLAUR plasminogen activator, urokinase receptor (PLAUR), transcript variant 2, 
mRNA. NM_001005376 2.6 
PROM1 prominin 1 (PROM1), transcript variant 4, mRNA. NM_001145852 2.3 
KITLG KIT ligand (KITLG), transcript variant a, mRNA. NM_003994 2.3 
CD3D CD3d molecule, delta (CD3-TCR complex) (CD3D), transcript variant 1, 
mRNA. NM_000732 2.1 
FLOT2 flotillin 2 (FLOT2), mRNA. NM_004475 2.0 
CD38 CD38 molecule (CD38), mRNA. NM_001775 2.0 
TEK TEK tyrosine kinase, endothelial (TEK), mRNA. NM_000459 1.9 
BMP7 bone morphogenetic protein 7 (BMP7), mRNA. NM_001719 1.9 
CXCR4 chemokine (C-X-C motif) receptor 4 (CXCR4), transcript variant 1, mRNA. NM_003467 1.9 
ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2 (ABCG2), mRNA. NM_004827 1.9 
FLT3 fms-related tyrosine kinase 3 (FLT3), mRNA. NM_004119 1.8 
CD24 CD24 molecule (CD24), mRNA. NM_013230 1.8 
IL8 interleukin 8 (IL8), mRNA. NM_000584 1.7 
SOX2 SRY (sex determining region Y)-box 2 (SOX2), mRNA. NM_003106 1.5 
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Suppl. Figure A.1: Ang-1 upregulated prostate CSC markers in DU-GFP-Tie-2 
cells. (A) DU145 constitutively expressing the Tie-2 protein (DU-Tie-2-GFP) was 
sorted by FACS using GFP as the marker. (B) Western blotting of prostate CSC 
markers (CD49f and Bmi-1) after Ang-1 treatment in DU-GFP and DU-Tie-2-GFP. 
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Suppl. Figure A.2: Tie-2 facilitated the adhesion of prostate cancer cells to bone 
(MG-63 and SaOS-2) and HUVEC cells. (A) Tie-2
High
 PC-3 cells were more 
adhesive to SaOS-2 cells when compared to Tie-2
Low 
PC-3 cells. (B) Effect of Tie-2 
inactivation on the adhesive ability of Tie-2
High 
PC-3 cells. Treatment with a Tie-2 
inhibitor (5 µM) prior to the adhesion assay significantly suppressed the adhesion 
ability of Tie-2
High
 cells, while the same treatment failed to affect the Tie-2
Low
 
population. (C & D) The addition of Tie-2 inhibitor  to DU-Tie-2-GFP cells 
drastically inhibited the adhesion ability of cells to MG-63 and HUVEC cells, but not 
in DU-GFP cells. Each experiment was repeated at least three times, and the results 
are presented as the mean ± SD. 
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Suppl.  Figure A.3: Localization of metastatic tumor in the mice with Tie-2
High
 
cell implantation. (A) Bioluminescence images of mice with tumor metastasis at 8 
weeks after the Tie-2
High
 cell implantation. (B) Ex vivo imaging of the metastatic 
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Suppl. Figure A.4: Model for the role of Tie-2 in prostate tumor metastasis. 
Ang-1/Tie-2 functions as an autocrine loop that regulates the stemness and 
quiescence of a rare population of Tie-2 positive prostate cancer cells. These cells, 
which are capable of adhering to endothelial cells and obsteoblasts, are highly 
metastatic in vivo and may be responsible for mediating tumor metastasis in vivo. 
Thus, targeting the Ang-1/Tie-2 autocrine loop with Tie-2 inhibitor may offer 
opportunities for inhibiting prostate tumor metastasis by eliminating the metastatic 
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3.7 Supplementary Materials and Methods 
Cell lines and culture conditions 
Prostate cancer cell lines PC-3, DU145, LNCaP and LAPC4 were obtained from 
ATCC (Rockville, MD, USA) and were maintained in RPMI 1640 medium 
(Invitrogen, Carlsbad, CA, USA) supplemented with 5% fetal bovine serum (FBS, 
Invitrogen) and 2% (wt/vol) penicillin-streptomycin P/S, Invitrogen); whereas 22Rv1 
was a generous gift from Prof. Franky Chan (The Chinese University of Hong Kong) 
and was maintained in RPMI 1640 medium supplemented with 10% FBS and 2% 
(wt/vol) P/S. C42B was kindly provided by Prof Leland Chung (Cedars-Sinai 
Medical Center) and was maintained in T-Medium (Invitrogen) supplemented with 
5% FBS and 2% P/S. MDA-PCa-2b was a kind gift from Dr Nora Navone (MD 
Anderson Cancer Center) and was maintained in BRFF-HPC1 medium (Athena 
Enzyme Systems) supplemented with 20% FBS and 1% P/S. Osteosarcoma cell lines 
MG-63 and SaOS-2 were obtained from ATCC and were maintained in Dulbecco’s 
modified Eagle’s medium (Invitrogen) (DMEM containing 10% FBS, 1% P/S) and 
McCoy’s 5a medium (Invitrogen) containing 10% FBS, 1% P/S respectively. Human 
Umbilical Vein Endothelial Cells (HUVEC) were purchased from ScienCell 
Research Laboratories, Carlsbad, CA, USA and were maintained in endothelial 
culture medium (ECM) supplemented with 5% FBS, 1% endothelial cell growth 
factor (ECGS) and 1% P/S (ScienCell Research Laboratories). All cell types were 
kept at 37
0
C in a 5% CO2 environment. 
 
Antibodies and reagents 
Tie-2 inhibitor, Hoechst33342 (HO) and Pyronin Y (PY) were purchased from Santa 
Cruz Biotechnology, Dallas, TX, USA. Recombinant Human Tie-2 Fc Chimera, CF 
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was purchased from R&D Systems, Minneapolis, MN, USA and Human Ang-1 
recombinant protein was purchased from PROSPEC, East Brunswick, NJ, USA. 
Gamma-tocotrienol (-T3) was provided by Davos Life Science Pty Ltd from 
Singapore, and was dissolved in absolute ethanol (100 mM). Cabazitaxel was 
purchased from Selleck, Houston, TX, USA and was dissolved in absolute ethanol 
(100 M). 
The following antibodies were used in this study: Phycoerythrin (PE) conjugated 
Tie-2 antibody and  Mouse IgG1 PE  Isotype Control (R&D Systems, Minneapolis, 
MN, USA); Human CD49f, pAKT and AKT antibodies (Cell Signalling Technology, 
Danvers, MA, USA); Bmi-1 antibody (Millipore, Billerica, MA, USA); p27 antibody 
(BD Biosciences); Tie-2, Actin and donkey anti-goat IgG-HRP antibody (Santa 
Cruz) and  HRP conjugated anti-mouse and anti-rabbit secondary antibodies (GE 
Healthcare, Buckinghamshire, UK). 
 
Microarray analysis 




 populations were prepared for microarray 
profiling, which was performed on a custom Agilent 4X180k oligo array. The 
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Chapter 4: Research Paper 2: Adipocytes 
promote prostate cancer stem 
cell self-renewal through a 
amplification of the 
cholecystokinin autocrine loop 
While the role of osteoblast in the development of prostate tumor bone metastasis 
have been well-established, little is known about the role of adipocytes within the 
bone marrow tumor microenvironment. For this reason, in this chapter, I have 
focused on the investigating whether  adipcoytes contribute to the CSC niche within 
the bone marrow. Through this study, I have established a novel 3D spheroid co-
culture model and subsequently used it to demonstrate the role of adipocytes in 
regulating the prostate CSC self-renewal and expansion. More importantly, I have 
shown that inactivation of both CCKBR and CTSB with specific inhibitors resulted 
in a significant suppression of the CSC-promoting effect of adipocytes. My study 
therefore demonstrated the underlying mechanism in the crosstalk between the 
prostate CSC and adipocytes. Meanwhile, further testing the effect of targeting this 
amplication loop may drive the development of a new treatment for advanced stage 
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4.1 Abstract 
Obesity has long been linked with prostate cancer progression, although the 
underlying mechanism is still largely unknown. Here, we report that adipocytes 
promote the enrichment of prostate cancer stem cells (CSCs) through a vicious cycle 
of autocrine amplification. In the presence of adipocytes, prostate cancer cells 
actively secrete the peptide hormone cholecystokinin (CCK), which not only 
stimulates prostate CSC self-renewal, but also induces cathepsin B production of the 
adipocytes. In return, cathepsin B facilitates further CCK secretion by the cancer 
cells. More importantly, inactivation of CCK receptor not only suppresses cathepsin 
B secretion by the adipocytes, but also synergizes the inhibitory effect of cathepsin B 
inhibitor on adipocyte-promoted prostate CSC self-renewal. In summary, we have 
uncovered a novel mechanism underlying the mutual interplay between adipocytes 
and prostate CSCs, which may help explaining the role of adipocytes in prostate 
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4.2 Introduction 
Prostate cancer is the second most common cause of solid tumours in men worldwide 
[203]. Despite recent advances in the detection of early prostate cancer, there 
remains no effective therapy for patients with metastatic disease. The majority of 
patients with advanced disease will respond initially to androgen ablation therapy. 
However, 75-80% of them will go on to develop bone metastasis and once the tumor 
established in the bone, the disease is considered as incurable [2, 204, 205]. 
 
Tumor metastasis develops when cancer cells disseminate into the circulation, 
colonize secondary tissues and redevelop into bulk tumors [4]. Recent evidence 
supports the idea that tumor metastasis originates from a rare population of cancer 
cells known as cancer stem cells (CSCs). CSCs are characterized by their highly 
invasive characteristics and by their ability to self-renew and differentiate into 
heterogeneous lineages of cancer cells [16]. The stemness of CSCs is highly 
dependent on the presence of a stem cell niche. Recent studies suggest that CSCs 
from breast cancer are capable of creating their own niche by recruiting 
mesenchymal stem cells derived from bone marrow, resulting in expansion of the 
CSC population within the primary tumor [206]. The same process is suggested to 
occur during the development of bone metastasis, whereby disseminated prostate and 
breast tumor cells with CSC properties have been found to occupy and manipulate 
the hematopoietic stem cell niche in bone marrow [207, 208]. Therefore, identifying 
the key components of the CSC niche that support prostate cancer metastasis may 
offer opportunities for new treatment strategies. 
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Emerging data from recent studies support that adipocytes play a key role in prostate 
tumor metastasis. For example, obesity, which is associated with abnormal growth 
and functions of adipocytes, has been shown to correlate strongly with tumor 
metastasis in prostate cancer patients. Meanwhile, high-fat diet has also been 
consistently shown to promote the development of prostate tumor metastasis [209]. 
Furthermore, adipocytes isolated from periprostatic adipose tissues were found to 
induce invasiveness of prostate cancer cells [28]. Recently, bone marrow adipocytes 
have also been reported to stimulate prostate tumor growth in bone via a fatty acids 
binding protein 4 (FABP4)-dependent mechanism [26]. Considering that adipocyte 
lineage cells were found to stimulate follicular stem cell expansion [154], it is 
possible that adipocytes may promote prostate tumor metastasis, possibly by 
contributing to the formation of a CSC niche within the tumor microenvironment. 
 
Here, we demonstrated for the first time the role of adipocytes in supporting self-
renewal of prostate CSCs. We found that co-culturing of prostate cancer cells with 
adipocytes resulted in CSC enrichment, which was associated with upregulation of 
cholecystokinin (CCK), a peptide hormone regulating fat digestion and satiety. CCK 
not only functions as an autocrine factor to promote CSC self-renewal, but also acts 
as a paracrine factor on adipocyte to stimulate the secretion of the cysteine protease 
cathepsin B (CTSB). Surprisingly, CCK secretion by the cancer cells was found to be 
induced by CTSB, suggesting that CCK and CTSB contribute to an 
autocrine/paracrine amplification loop that mediates the mutual interplay between 
prostate CSCs and adipocytes. 
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4.3 Results 
4.3.1 Adipocytes promote prostate CSC self-renewal 
In order to understand the mutual interplay between adipocytes and prostate CSCs 
population, mouse prostate cancer cell line (TRAMP-C1) was allowed to grow in a 
non-adherent condition in the presence or absence of adipocytes (derived from the 
3T3-L1 pre-adipocyte cell line). Co-culturing with fully differentiated adipocytes 
strongly induced the self-renewal ability of the TRAMP-C1 cells, as evidenced by 
the drastic induction of spheroid formation (1 vs 12) under co-culture conditions 
(Fig. 4.1A&B). Moreover, secondary spheroid formation was also induced in the 
presence of adipocytes (Fig. 4.1C). Similarly, adipocytes also promoted spheroid 
formation of three other mouse cell lines TC1-T5, RM1 and RM1-BM (Suppl. Figure 
B.1). Apart from increasing the number of prostaspheres formed, the size of 
individual prostaspheres was also significantly increased by co-culturing with 
adipocytes (Figure 4.1B). Meanwhile, following dissociation of primary 
prostaspheres and subsequent reseeding in the presence of adipocytes resulted in 
significantly induced the formation of secondary prostaspheres (Figure 4.1C&D), 
further confirming the effect of adipocytes on prostate CSC self-renewal ability. 
Consistently, bone marrow derived adipocytes (OP9) also promoted the 
prostatsphere formation of TRAMP-C1 cells to a similar extent (Suppl. Figure B.2), 
suggesting that the CSC promoting effect may be common among adipocytes derived 
from different origins.  
To validate our findings, western blotting and flow cytometry analysis of common 
CSC markers were performed. As shown in Figure 4.1E, protein expression of 
Notch1, CD49f, Sca-1 and Nanog in TRAMP-C1 cells was significantly upregulated 
after co-culturing with adipocytes. Furthermore, the percentage of cells expressing 
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the two putative CSC markers CD49f and Sca-1 was significantly upregulated after 
co-culturing with adipocytes (Figure 4.1F). These results confirm that adipocytes 
actively promote self-renewal of prostate CSCs, leading to subsequent expansion of 
CSC population.  
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Figure 4.1: Adipocytes promote prostate CSC self-renewal. (A) Adipocytes 
stimulate formation of prostaspheres. TRAMP-C1 cells were seeded in ultra-low 
attachment plates in the presence or absence of 3T3-L1-derived adipocytes. After 7 
days, prostaspheres formed were counted under the microscope. (B) Representative 
images of the prostaspheres. (C&D) Primary TRAMP-C1 prostasphere were 
dissociated and were allowed to grow as secondary prostaspheres in the presence of 
adipocytes. (E&F) Expression of CSC markers by TRAMP-C1 cells that grow alone 
or co-culturing with the adipcoytes were examined by western blotting (Notch 1, 
CD49f, Sca-1 and Nanog) and flow cytometry (CD49f and Sca-1) respectively. The 
results are presented as the mean ± SD from triplicate experiments in the bar chart 
(right panels). (p values: * < 0.05, ** < 0.005, *** < 0.0005). 
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4.3.2 Adipocytes induce the CCK autocrine loop in prostate CSCs 
To understand the underlying mechanism that drive the active self-renewal of 
prostate CSCs under the co-culture conditions, cDNA microarray analysis was 
performed to compare the gene expression profile of TRAMP-C1 cells that grow 
alone or in the presence of adipocytes. As expected, expression of a number of 
known stemness factors such as ALDH1A1, GFI-1 or ITGA2 were highly induced in 
TRAMP-C1 cells in the presence of adipocytes (Figure 4.2A and Suppl. Figure B.3). 
However, the gene that showed the highest level of induction was found to encode 
the protein CCK (Suppl. Table B.2), a peptide hormone expresses mainly by the 
mucosal epithelium in response to consumption of high-fat diet. Subsequent analysis 
with RT-PCR and ELISA confirmed that both CCK mRNA and protein secretion 
were upregulated in prostate cancer cells in the presence of adipocytes (Figure 
4.2B&C and Suppl. Figure B.4). Surprisingly, prostate cancer cell lines were found 
to actively expressing the CCK receptor CCKBR (Figure 4.2D). Since activation of 
CCKBR has recently been shown to promote the stemness of colon cancer cells 
[210], it is possible that the induction of CCK expression by adipocytes may lead to 
the activation of an autocrine loop and as a result promote CSC self-renewal. Indeed, 
while the level of CCK mRNA in both TRAMP-C1 and LNCaP cells was 
undetectable, the corresponding bone metastatic sublines (i.e. TC1-T5 and C42B), 
which are enriched with CSC population (Suppl. Figure B.5), were both found to 
actively express CCK transcript (Figure 4.2E). Meanwhile, treatment with human 
recombinant CCK not only induced the expression of CSC marker in TRAMP-C1 
cells (Figure 4.2F), but also promotes the formation of prostasphere by the cells 
(Figure 4.2G), indicating the importance of CCK in regulating prostate CSC self-
renewal. To confirm our findings, TRAMP-C1 cells were treated with a CCKBR 
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specific inhibitor (i.e. YM022). As shown in Figure 2H, inhibition of CCKBR was 
found to suppress CSC marker expression in TRAMP-C1 cells. More importantly, 
CCKBR inhibition was found to suppress the promoting effect of adipocytes on 
spheroid formation of the cancer cells (Figure 4.2I), supporting that adipocytes 
stimulate prostate CSC self-renewal by facilitating the activation of the 
CCK/CCKBR autocrine loop. 
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Figure 4.2: Adipocytes induce the cholecystokinin autocrine loop in prostate 
CSCs. (A) Genes upregulated in TRAMP-C1 cells after co-culturing with adipocytes 
were deteremined by cDNA microarray analysis and the top 50 genes were displayed 
as a heat map. (B) Upregulation of CCK mRNA in TRAMP-C1 cells under co-
culture condition was validated with RT-PCR. (C) ELISA was performed to confirm 
the induction of CCK production in TRAMP-C1 cells after co-culturing with 
adipocytes. (D) CCKBR expression was analysed in mouse and human prostate 
cancer cell lines (TRAMP-C1, TC1-T5, LNCaP and C42B) using western blotting. 
(E) CCK is upregulated in metastatic prostate cancer cells. mRNA level of CCK in 
TRAMP-C1, LNCaP and their corresponding metastatic sublines  (TC1-T5 and 
C42B) were analysed by RT-PCR. (F) Effect of CCK treatment on CSC marker 
expression in prostate cancer cells. TRAMP-C1 cells were treated with recombinant 
CCK for 48 hours and the expression of CD49f was examined using Western blotting 
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(left panel) and the band intensity was presented as in the bar chart (right panel). (G) 
CCK promotes prostasphere formation by TRAMP-C1 cells. TRAMP-C1 cells were 
seeded in an ultra-low attachment plate in the presence or absence of human 
recombinant CCK. After 7 days, prostaspheres formed were counted under the 
microscope. (H) Inhibition of CCKBR downregulated CSC marker expression 
(CD49f) in TRAMP-C1 cells. Cells treated with either the vehicle or YM022 were 
lysed and subjected to Western blot analysis antibodies against the indicated proteins 
(left panel) and the band intensity was presented as in the bar chart (right panel). (I) 
Inhibition of CCKBR abolishes the effect of adipocytes on prostasphere formation. 
TRAMP-C1 cells co-cultured with adipocytes were treated with different doses of 
the YM022 (5 and 10 µM) and the prostaspheres formed under each condition were 
counted under the microscope. All experiments were repeated at least three times, 
and the results are presented as the mean ± SD. (p values: * < 0.05, ** < 0.005, *** < 
0.0005). 
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4.3.3 CCK stimulates CTSB secretion of the adipocytes 
Since CCK has been shown to regulate the function of adipocytes through activation 
of the CCKBR, we therefore speculate that by actively secreting CCK, prostate CSCs 
may also influence the co-cultured adipocytes, possibly in a way that favour their 
self-renewal ability. Indeed, mass spectrometry analysis of the conditioned medium 
(CM) from adipocytes before and after co-cultured with prostate CSCs revealed that 
the cysteine protease CTSB, which plays an important role in the development and 
progression of prostate cancer, was among the proteins induced in adipocytes under 
the co-culture condition (Figure 4.3A). Subsequent analysis of the conditioned 
medium with ELISA further confirmed that CTSB secretion was upregulated in 
adipocytes that have been co-cultured with prostate CSCs (Figure 4.3B), although the 
mRNA level of CTSB was not induced under the same condition (Figure 4.3C). 
Similarly, CTSB secretion, but not the mRNA level (data not shown), was induced in 
adipocytes that were treated with recombinant CCK (Figure 4.3D). However, the 
effect of the recombinant CCK was abolished in the presence of the YM022 (Figure 
4.3E), confirming that CCK induced CTSB through activation of the CCKBR.  
  




Figure 4.3: CCK stimulates CTSB secretion by the adipocytes. (A) Protein 
secretion profiles of 3T3-L1-derived adipocytes before or after being co-cultured 
with TRAMP-C1 cells was determined by mass spectrometry. Proteins upregulated 
under the co-culture condition were listed in Table A. (B&C) ELISA and RT-PCR 
were performed to validate the induction of CTSB expression in adipocytes after co-
culturing with TRAMP-C1 cells. (D&E) Secretion of CTSB in adipocytes is 
regulated by CCK. (D) 3T3-L1-derived adipocytes were treated with CCK 
recombinant protein (0.2µg/ml) for 4 hours and the level of CTSB in the conditioned 
medium was analysed by ELISA. (E) Addition of YM022 (1 and 5 µM) completely 
abolished the effects of CCK on CTSB induction. Each experiment was repeated at 
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least three times, and the results are presented as the mean ± SD. (p values: * < 0.05, 
** < 0.005). 
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4.3.4 CCK and CTSB contribute to an autocrine/paracrine amplication loop 
One of the key functions of cathepsin family proteins is the regulation of peptide 
hormone release and activation [211]. For example, CSTB has been shown to 
promote the liberation of thorexine at the apical membrane [212]. Meanwhile, 
cathepsin L1 was also found to induce the processing of pro-CCK, leading to an 
increase in the secretion of the active CCK [213]. Although CTSB has not been 
reported to regulate CCK secretion, we found that treatment of TRAMP-C1 cells 
with recombinant CTSB resulted in significant upregulation of CCK level in the 
conditioned medium without affecting CCK mRNA levels (Figure 4.4A). 
Meanwhile, inhibition of CTSB significantly suppressed CCK production by the 
cancer cells, further supporting that CTSB regulates CCK secretion (Figure 4.4B). 
Since CCK is also capable of inducing CTSB production of adipocytes, we 
anticipated that this autocrine/paracrine amplification loop may play a key role in 
sustaining the adipocyte-promoted prostate CSC self-renewal. Consistent with our 
hypothesis, the promoting effect of adipocytes on prostasphere formation was 
significantly suppressed in the presence of CA-074ME (Figure 4.4C). Meanwhile, 
CA-074ME was found to significantly enhance the effect of YM022 against 
prostasphere formation (Figure 4.4D). These results clearly indicate the critical role 
of this novel autocrine/paracrine loop in mediating the effect of adipocytes on 
prostate CSC self-renewal as summarized in Figure 4.4E. 
 Dissecting the prostate cancer  stem cell niche inside the bone marrow. 127
 
 
Figure 4.4: CCK and CTSB contributes to an autocrine/paracrine amplification 
loop. (A) CTSB regulates the secretion of CCK by prostate cancer cells. TC1-T5 
cells were treated with CTSB recombinant protein (0.2µg/ml) for 4 hours and the 
level of CCK in the conditioned medium was determined by ELISA. (B) Inhibition 
of CTSB with CA-074ME (10µM) suppresses CCK secretion in TC1-T5 cells. (C) 
CTSB inhibition suppressed the promoting effect of adipocytes on prostasphere 
formation in a dose dependent manner. TRAMP-C1 cells co-cultured with 3T3-L1-
derived adipocytes were treated with different dosage of CA0-74ME (5, 10 and 
20µM). Prostaspheres were counted and imaged at day 7. (D) CTSB inactivation 
sensitizes prostate CSCs to YM022 treatment. TRAMP-C1 cells co-cultured with 
3T3-L1-derived adipocytes were treated with the YM022 alone or in combination 
with CA-074ME. After 7 days, prostaspheres formed were counted and imaged 
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under the microscope. (E) Summary of the proposed role of adipocytes on prostate 
CSC maintenance. Each experiment was repeated at least three times, and the results 
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4.4 Discussion 
The frequent invasion of local tumor into periprostatic adipose tissues and the 
metastasis of advanced tumors into the adipocyte-rich bone marrow clearly suggest 
the importance of adipose tissues during prostate cancer progression [20, 214]. What 
is not yet clear is how prostate cancer cells interact with the adipocytes to support 
their eventual expansion into metastatic tumor. Here, we report for the first time that 
adipocytes actively interplay with prostate CSCs through amplification of a novel 
CCK autocrine loop, leading to rapid enrichment of the CSC population. 
 
Similar to normal stem cells, the stemness of prostate CSCs is highly dependent on 
the presence of a stem cell niche [17]. The stromal cells within the primary prostate 
tumor appear to play a key role in promoting the tumorigenicity of the prostate 
cancer cells, as evidenced by the ability of cancer associated fibroblasts in 
transforming normal prostate epithelial cells [215]. Similarly, our finding that 
adipocytes actively stimulate prostate CSC self-renewal support the notion that 
adipose tissues may contribute to a metastatic niche necessary for the maintenance of 
prostate CSCs. Since obesity is associated with adipocyte dysfunction and abnormal 
adiposity, the resulting enrichment of the metastatic niches (i.e. the periprostatic 
adipose tissues and bone marrow fat)  may in turn contribute to the frequent tumor 
metastasis and poor prognosis observed in obese prostate cancer patients [209]. 
 
The significant upregulation of CCK mRNA in prostate cancer cells upon co-
cultured with adipocytes suggests that CCK is playing an important role in mediating 
the effect of adipocytes on CSC self-renewal. Expression of CCK was believed to be 
restricted to the enteroendocrine cells and to specialized neurons within the brain 
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[216, 217]. It is therefore surprising that CCK and its receptor were both found to be 
expressed by prostate cancer cells. Our study therefore represents the first to discover 
the autocrine function of CCK in the maintenance of prostate CSCs. Exactly how 
CCK promotes the stemness of prostate CSCs is still unclear, although the binding 
and activation of CCKBR by gastrin, a hormone peptide structurally related to CCK, 
was found to regulate the proliferation of normal and malignant colon stem cells 
through suppression of both BMP-2 and Id4 expression [210]. Since CCK also binds 
to and activates CCKBR, it is possible that CCK may act through the same 
downstream m signalling pathway.  
 
Dietary fat is the major risk factor not only for obesity, but also for prostate cancer 
progression [218, 219]. Intake of dietary fat is known to induce a rapid upregulation 
of CCK expression by the enteroendocrine cells within the intestine [220]. Therefore, 
long term high-fat diet consumption is expected to result in chronic elevation of 
serum CCK level. Indeed, in a recent study, mice that consumed a high-fat diet were 
found to have serum CCK level ten folds higher than that of the control group [221]. 
In pancreatic cancer, CCK expression was also found to be associated with larger 
tumors and a higher incidence of metastasis [221, 222].  Considering that prostate 
cancer cells also express CCKBR and respond to CCK stimulation, the effects of a 
high-fat diet on prostate tumor progression reported in a previous study [223] may 
well be a consequence of CCK elevation. Therefore, exposing the cancer cells to 
high lipid content (i.e. high-fat diet or co-culturing with adipocytes) may promote the 
CCK-autocrine loop and further driven the expansion of prostate CSCs.  
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It is worth noting that CCK not only regulates fat and protein digestion, but also 
controls the level of satiety. In an animal study, systemic administration of CCK was 
found to induce anorexia [224]. Meanwhile, serum CCK level was found to be 
significantly higher in older individuals [225], and is suggested to contribute to 
aging-associated anorexia. Interestingly, according to previous studies, CCK and 
leptin worked synergistically in reducing the short-term food intake [226] through 
activation of Src/PI3K and JAK2/PI3K/STAT3 signaling pathway respectively [227]. 
Since leptin is an adipokine that actively secreted by adipocytes [152], it is possible 
that CCK secreted by cancer cells may work synergistically with leptin in the 
development of anorexia commonly found in advanced stage prostate cancer 
patients, although further examination of serum CCK and leptin levels in prostate 
cancer patients are necessary to confirm this hypothesis. 
 
Our findings suggest that the secretion of CCK by prostate CSCs may also play roles 
in modulating the function of adipocytes, possibly in a way that further facilitates 
CSC expansion. One of the key pieces of evidence is the stimulation of CTSB 
secretion by the adipocytes, which in turn further promotes the secretion of CCK by 
the cancer cells. Our discovery of this seemingly paracrine/autocrine amplification 
loop may help in explaining the mutual interplay between prostate cancer cells and 
adipocytes. More importantly, despite the presence of adipocytes, disruption of this 
loop by means of inactivating either CCK receptor or CTSB can significantly inhibit 
prostate CSC expansion, clearly demonstrating the therapeutic potential of this 
paracrine/autocrine amplification loop for targeting CSC population.  
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In summary, we have identified a novel mechanism that mediates the interaction 
between adipocytes and prostate cancer cells, which may offer opportunities for the 
development of new treatments against metastatic prostate cancer.  
 
4.5 Materials and Methods 
Spheroid formation assay 
The spheroid formation assay was modified from a previously reported protocol 
[201, 228]. Briefly, cells were harvested and counted using a Scepter
™
 Automated 
Cell Counter (Millipore, Billerica, MA, USA). Four hundred cells were added to 
each well of a 24-well ultra-low attachment plate (Sigma-Aldrich, St. Louis, MO, 
USA). Adipocytes differentiated from the 3T3-L1 cells were then added into a cell 
culture insert (0.4 M) (Millipore) placed inside the well.  Cells were grown in 
DMEM/F12 (Invitrogen, Carlsbad, CA, USA) supplemented with 10 g/mL insulin 
(Sigma-Aldrich), B27 (Invitrogen), 80 ng/mL EGF (Sigma-Aldrich) and 40 ng/mL 
basic FGF (Invitrogen).  The number of spheroid formed was counted at Day 7 or at 
the end of the treatment. Each experiment was performed in triplicate and was 
repeated at least 3 times, with each data point represents the mean and SD. Statistical 




Experimental procedures have been described in our previous studies [197].                                                                                                                        
Firstly, cell pellets were collected and lysed with lysis buffer (Cell Signalling 
Technology, Danvers, MA, USA) containing 100 µM phenylmethylsulfonyl fluoride 
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(PMSF; Sigma-Aldrich). The cell lysates were quantified using the Pierce™ 
BCAProtein Assay Kit (Thermo Fisher Scientific, Rockford, IL, USA) before 
loading onto a SDS-polyacrylamide gel. The resolved proteins were then transferred 
onto a PVDF membrane (Millipore), subsequently blocked the membrane with 10% 
skim milk in TBST-T buffet at room temperature. After the blocking, the membrane 
was probed with the indicated antibody for 1 hour at room temperature prior to being 
washed with TBS-T buffer. The membrane was then incubated with the 
corresponding secondary antibodies for another hour at room temperature. After 
washing with TBS-T buffer, the membrane was incubated with Immobilon Western 
Chemiluminescent HRP Substrate (Millipore), and the signals were visualized and 
quantified using a Bio-Rad ChemiDoc™ XRS Gel Documentation System. 
 
Flow cytometry analysis  
Cells were collected, washed twice with phosphate-buffered saline (PBS) and 
subsequently resuspended in 50 l of fluorescence-activated cell sorting  (FACS) 
buffer (0.02% sodium azide and 2% FBS in PBS) before incubating with the 
fluorescent dye-conjugated antibodies at 4°C in the dark for 30 minutes. After 
incubation, the cells were washed twice with PBS and resuspended in 200 l of 
FACS buffer. Fluorescent signal was determined with the BD™ LSR II and the 
results were analysed using the KALUZA software. 
 
Microarray analysis 
TRAMP-C1 cells that were grown alone or co-cultured with adipocyte were lysed for 
RNA extraction with the RNeasy Mini Kit (Qiagen, Germantown, MD, USA). The 
resulting RNA was used for the generation of labeled cDNA based on the protocol 
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described earlier [202]. cDNA was probed against the Mouse GE 44K v2 Microarray 
G2519F-026655 (Agilent Technologies, Santa Clara, CA, USA) with the standard 
procedures described by the manufacturer, and the signals were read by the Agilent 
scanner and analysed with the Genespring software. 
 
Real Time- Polymerase Chain Reaction (RT-PCR) 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Germantown, MD, 
USA) and 2 g of the resulting RNA was used to synthesize cDNA using the 
SuperScript® III First-Strand Synthesis Systems (Invitrogen). RT-PCR was carried 
out with the ViiA™ 7 Real-Time PCR System (Applied Biosystems, Foster City, 
CA, USA). Sense and anti-sense primers specific for the genes of interest are listed 
in Suppl. Table B.1. The transcript level of ribosomal protein L32 (RPL32) was used 
as an internal control. To quantify CCK transcript level in human prostate cancer cell 
lines, copy number of CCK mRNA was calculated with a standard curve. 
  
Liquid chromatography–Mass Spectrometry (LC-MS/MS) 
Concentrated conditioned media (from adipocytes before and after co-culturing with 
TRAMP-C1 prostasphere) was quantitated by Pierce™ BCA Protein Assay Kit 
before being separated on a SDS-PAGE gel and visualized by colloidal coomassie. 
Protein gel slices (1 mm) were excised using a clean gel cutter (The Gel Company 
San Francisco, CA,USA), transferred to 96-well U bottom plate containing a solution 
of 50% acetonitrile: 25mM NH4HCO3 for destaining. Samples were reduced with 
20mM DTT followed by alkylation with 50mM IAA. The samples were equilibrated 
to pH [229]. 
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4.6 Supplementary Tables and Figures 
Suppl. Table B.1: List of the primers used in this study. 
  
Suppl. Table B.2: Top-Ten most upregulated genes in TRAMP-C1 after co-
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Suppl. Figure B.1: Effect of adipocytes on self-renewal of additional mouse 
prostate cancer cell lines. (A&B) Prostasphere formation assay was performed with 
different mouse prostate cancer cell lines (TC1-T5, RM1 and RM1BM) in the 
presence or absence of 3T3-L1-derived adipocytes, grown in inserts. Each 
experiment was repeated at least three times, and the results are presented as the 
mean ± SD. (p values: * < 0.05, *** < 0.0005).  
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Suppl. Figure B.2: Bone marrow-derived adipocytes promote prostate CSC self-
renewal. (A&B) TRAMP-C1 cells were seeded in ultra-low attachment plate in the 
presence or absence of adipocytes derived from the bone marrow stromal cell line 
OP9. After 7 days, prostaspheres formed were counted and imaged under the 
microscope. The results are presented as the mean ± SD from triplicate experiments. 
(p values: ** < 0.005). 
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Suppl. Figure B.3: CSC markers are upregulated in mouse prostate cancer cells 
that co-cultured with adipocytes. RT-PCR analysis of CSC markers (ALDH1A1, 
ANG-1, DKK2, GFI-1, ITGA2, ITGA6, PTHLH and STCL)  mRNA level in (A) 
TRAMP-C1 and (B) TC1-T5 cells that grown alone or co-cultured with adipocytes. 
The results are presented as the mean ± SD from triplicate experiments. (p values: * 
< 0.05, ** < 0.005, *** < 0.0005). 
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Suppl. Figure B.4: CCK mRNA level is upregulated in mouse prostate cancer 
cells that co-cultured with adipocytes. RT-PCR analysis of CCK mRNA level in 
(A) TC1-T5, (B) RM1 and (C) RM1-BM cells that grow alone or co-cultured with 
adipocytes. The results are presented as the mean ± SD from triplicate experiments. 
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Suppl. Figure B.5: Enrichment of CSCs in the bone metastatic cell lines TC1-
T5. (A) Self-renewal ability of TRAMP-C1 and its bone metastatic derivative TC1-
T5 were examined by prostasphere formation assay. Prostaspheres formed at day 7 
were counted and imaged under a microscope. (B) Western blotting was performed 
to examine the level of CSC markers expressed in the two cell lines. (C) mRNA level 
of stem cell transcription factors (ALDH1A1, DKK2, GFI-1 and PTHLH) were 
analyzed with RT-PCR. Each experiment was repeated at least three times, and the 
results are presented as the mean ± SD. (p values: * < 0.05, ** < 0.005, *** < 
0.0005). 
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4.7 Supplementary Materials and Methods 
Cell lines and culture conditions 
Mouse prostate cancer cell line TRAMP-C1 was obtained from ATCC (Rockville, 
MD, USA) and was maintained in RPMI 1640 medium (Invitrogen, Carlsbad, CA, 
USA) supplemented with 10% fetal bovine serum (FBS, Invitrogen) and 1% (wt/vol) 
penicillin-streptomycin P/S, Invitrogen); whereas TC1-T5 was established as 
described in a previous study [230]. RM1 and RM1-BM were generous gifts from Dr 
Carl Power (University of New South Wales) and these cells were maintained in 
Dulbecco’s modified Eagle’s medium (Invitrogen) (DMEM containing 10% FBS, 
1% P/S). Mouse pre-adipocyte (3T3-L1) and bone marrow stromal cell lines (OP9) 
were obtained from ATCC and were maintained in DMEM medium containing 10% 
FBS and 1% P/S and Minimum Essential Medium (MEM) α (Invitrogen) 
containing20% FBS, 1% P/S respectively. Human prostate cancer cell line LNCaP 
was obtained from ATCC and was maintained in RPMI 1640 medium supplemented 
with 5% FBS and 1% P/S. C42B was kindly provided by Prof Leland Chung 
(Cedars-Sinai Medical Center) and was maintained in T-Medium (Invitrogen) 
supplemented with 5% FBS and 2% P/S. All cell lines were kept at 37
0
C  in a 5% 
CO2 environment. 
 
Antibodies and reagents 
Human recombinant CCK protein was purchased from Tocris Biosciences (Bristol, 
United Kingdom). Human and mouse recombinant CTSB were purchased from R&D 
Systems (Minneapolis, MN, USA). CCKBR (YM022) and CTSB inhibitor (CA-
074ME) were purchased from Tocris Biosciences and were dissolved in DMSO.  
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The antibodies against Notch 1, CD49f (Cell Signalling Technology, Danvers, MA, 
USA), Sca-1 (R&D Systems), CCKBR (for Immunohistochemistry, Atlas Antibody, 
Stockholm, Sweden), Gama-tubulin (Sigma-Aldrich, St. Louis, MO, USA), Nanog, 
CCKBR and actin (Santa Cruz Biotechnology, Dallas, TX, USA) were used in this 
study. Phycoerythrin (PE) conjugated Sca-1 antibody and 647 conjugated human 
CD49f were both purchased from BD Biosciences (San Jose, CA, USA).  
 
Adipocyte differentiation 
To obtain fully differentiated adipocytes, 3T3-L1 and OP9 cells were seeded into a 
6-well plate at a confluency of 80%. Differentiation was induced with StemPro® 
Adipogenesis Differentiation Kit (Invirtrogen) by following the manufacturer’s 
instructions. Adipocyte differentiation medium was changed every 3 days, and the 
fully differentiated adipocytes were collected 9 days after the induction. 
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Chapter 5: Conclusions and Future Work                                       
Prostate cancer preferentially metastasizes to bone, which accounts for its high 
mortality. Considerable effort has been expended in attempting to understand the 
mechanisms underlying prostate tumor bone metastasis; however, little is known 
about how these cells disseminate into the circulation and colonize within bone. 
There is ample evidence to suggest that CSCs, which share many similar 
characteristics with HSCs, may play an important role in the development of prostate 
tumor bone metastasis and treatment resistance. Apart from being capable of self-
renewing, CSCs can also enter a quiescent state, thereby protecting themselves from 
conventional therapies like chemotherapy and radiotherapy. Therefore, targeting 
CSCs may offer new opportunities for improving the treatment outcome of patient 
with advanced stage prostate cancer.   
 
Previously, CSCs were found to hijack the bone marrow HSC niche to support their 
survival and growth. There are various cell types that reside within the bone marrow, 
with osteoblasts and adipocytes comprising the two major cellular components. 
Although both cell types have been suggested to play roles in prostate cancer 
progression, the underlying mechanisms remain largely unknown.  
 
Since osteoblasts actively secrete the cytokine Ang-1, the discovery in the first part 
of my project that prostate CSCs express the Tie-2 protein, a membrane receptor 
tyrosine kinase activated by Ang-1, represents a novel finding which may help in 
understanding how osteoblasts regulate prostate CSC maintenance. Moreover, I 
found that Tie-2 was highly expressed in more metastatic and aggressive human 
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prostate cancer cell lines. Apart from that, I found that Tie-2 receptors not only were 
expressed in PC-3 xenograft tumor tissue that grew within a humanized bone micro-
environment in NOD-SCID mice, but also in human prostate tumors that 
metastasized to the bone, indicating the importance of Tie-2 in the development of 
prostate tumor bone metastasis.  
 
Next, I have further identified the role of Tie-2 in prostate CSCs maintenance. 
According to previous studies, Ang-1/Tie-2 was found to regulate the stemness and 
quiescence  state of HSCs. Consistent with these findings, I discovered that Tie-2
High
 
prostate cancer cells not only express higher level of quiescent and stem cell 
markers, but are also more resistant to the chemodrug, cabazitaxel. Meanwhile, my 
finding suggests that the Ang-1/Tie-2 signalling pathway regulates prostate CSC 
maintenance through activation of the downstream pathway, Akt. Since PI3K/Akt is 
one of the well-known signalling pathways that takes part in regulating both HSC 
and CSC maintanence, my findings further support the importance of Ang-1/Tie-2 in 
regulating the stemness and quiescence of prostate CSCs.  
 
Over the past decades, the Ang-1 protein secreted by cancer cells was regarded as a 
paracrine factor that mediates tumor angiogenesis. My work suggests that Ang-1 also 
functions as an autocrine factor and thus, targeting this loop has the potential to 
eliminate the CSC population. My discovery is expected to open a new research 
paradigm on the functional role and therapeutic potential of the Ang-1/Tie-2 
autocrine loop. 
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Consistent with previous studies, Tie-2
High
  prostate cancer cells were more adherent 
to osteoblast and endothelial cells, suggesting that Ang-1/Tie-2 signalling pathway 
may play roles in intravasation or extravasation of tumor cells during the 
development of prostate tumor bone metastasis. Indeed, I have demonstrated that 
Tie-2
High
 prostate cancer cells, but not the Tie-2
Low
 population, were able to form 
metastatic tumors (2 bone metastasis and 1 kidney metastasis). In this study, 
therefore I provide solid data to support the critical role of Tie-2 in prostate tumor 
metastasis. I believe that the present study not only describes a major breakthrough 
in understanding the mechanism underlying tumor metastasis, but also highlights the 
therapeutic potential of inactivating the Ang-1/Tie-2 pathway in the treatment of 
prostate cancer.  
 
To further confirm the function of Tie-2 in bone metastasis, an ideal approach is to 
inject the Tie-2 overexpressing DU145 cells into the NOD-SCID mice and 
investigate whether the ectopic Tie-2 expression promote bone metastasis of the 
DU145 cells. Meanwhile, since a specific inhibitor against Tie-2 is currently 
undergoing Phase II clinical trial, it will be timely to validate whether a Tie-2 
inhibitor can suppress prostate tumor bone metastasis in an in vivo animal model that 
have been developed as mentioned in Chapter 3. Furthermore, since, Tie-2
High
 
prostate cells were found to be more metastatic, examination of Tie-2 expression in 
circulating tumor cells (CTCs), which disseminate into the blood stream and 
subsequently developed as metastatic tumors, may help to predict the development of 
bone metastasis.  
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Adipocytes within the periprostatic tissue or inside the bone marrow have both been 
suggested to play roles in prostate cancer development and progression;  however, it 
is not clear if adipocytes regulate prostate CSC self-renewal and homing. In the 
second part of my project, I have confirmed the effect of adipocytes on prostate CSC 
self-renewal, as evidenced by induction of prostasphere formation after co-culturing 
with adipocytes using a 3D spheroid co-culture model.  
 
Most importantly, I have identified a novel CCK/CCKBR autocrine loop in prostate 
CSCs that can be triggered by adipocytes. I found that CCK expression was induced 
in prostaspheres after co-culturing with adipocytes. Meanwhile, both mouse and 
human bone metastatic prostate cell lines were found to express higher level of CCK 
when compared to their non-metastatic parental lines, further supporting the 
association between CCK and tumor metastasis. Moreover, the CCK receptor, 
CCKBR was found to be expressed in human prostate cancer bone metastasis tissue 
sections. Besides that, there are already have the data to support the role of 
CCK/CCKBR in CSC self-renewal in gastric and pancreatic cancer. In this study, I 
have provided solid data to confirm the role of this pathway in regulating prostate 
CSCs. Since targeting this loop with a specific inhibitor can eliminate the effect of 
adipocytes on CSC expansion, my finding is expected to drive the development of a 
new treatment against metastatic prostate cancer. 
 
Cell-cell comunication is one of the hottest topics over the past decades. In this 
study, I have demonstrated for the very first time how adipocytes promote prostate 
CSC self-renewal through a vicious cycle of CCK and CSTB secretion. Our results 
suggest that CSTB, which is a well known CSC factor, can be secreted by adipocytes 
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and its secretion from adipocytes can be triggered by CCK from the CSC population. 
In return, CSTB was found to induce CCK secretion by the CSC population, 
supporting that both CCK and CTSB contribute to an autocrine/paracrine 
amplification loop and may explain how the crosstalk occurred between adipocytes 
and CSC population. Furthermore, the combination of CCKBR and CTSB inhibitors 
contributed to a synergistic effect on elimination of the CSC population, further 
confirming the importance of both CCK and CTSB in regulating CSC self-renewal.    
 
Although I have identified crosstalk between adipocytes and cancer cells using a 3D 
co-culture model, further investigation with both CCK and CTSB inhibitors in a 
mouse xenograft model is crucial to demonstrate the therapeutic potential of these 
inhibitors against metastatic prostate cancer. Thus, future work can focus on testing 
the combined effect of CCK and CTSB inactivation against tumor metastasis with in 
vivo prostate xenograft models. Apart from the therapeutic prospective, CCK and 
CTSB are secretory proteins that can be found in human serum and thus can serve as 
prognostic markers for predicting the development of bone metastasis in patients 
with advanced prostate cancer.  
 
Overall, this project has successfully uncovered new roles and mechanisms of action 
of both osteoblasts and adipocytes in prostate CSC self-renewal and the development 
of bone metastasis as summarized in Figure 5.1. Therefore, further preclinical studies 
that target these key signalling pathways (i.e. Ang-1/Tie-2 and CCK/CCKBR) 
identified in my study may result in the development of effective treatments against 
this most deadly form of prostate cancer. 
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Figure 5.1: Model for the role of osteoblasts and adipocytes in prostate tumor 
metastasis. Osteoblasts and adipocytes are the two major cellular components in the 
bone marrow. Both cell types were found to regulate quiescence and self-renewal of 
prostate CSCs via two specific signalling pathways: Ang-1/Tie-2 and CCK/CCKBR. 
I believe that further testing the effect of Tie-2 and CCKBR inhibitors in pre-clinical 
tumor metastatic models may help in the design of an effective treatment regimen 
against prostate cancer. 
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